Curriculum Vitae - University of Pittsburgh School of Pharmacy

Curriculum Vitae September 2006
Gordon J. Vanscoy
Office
Addresses: University of Pittsburgh University Pharmacotherapy Associates, LLC
725 Salk Hal l 105 Monroeville Blvd.
Pittsburgh, PA 15261 Monroeville, PA 15146
gvanscoy@pitt.edu gvanscoy@upa-llc.com
EDUCATION, TRAINING & CREDENTIALS
1999 Certified Anticoagulation Care Provider CACP
1988-1991 University of Pittsburgh Katz Graduate School of Business MBA
1987 University of Pittsburgh Geriatric Education Center Fellowship
1985-1986 Mercy Hospital of Pittsburgh Residency
1984-1986 Duquesne University School of Pharmacy PharmD
1978-1984 University of Pittsburgh School of Pharmacy BS Pharm
POSITIONS AND APPOINTMENTS
1992- Chairman and Chief Executive Officer,
University Pharmacotherapy Associates, L.L.C., Monroeville, Pennsylvania
2006- Associate Dean for Business Innovation,
Associate Professor (part-time), Department of Pharmacy and Therapeutics,
University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania
2005- Vice-Chairman of the Board (volunteer)
American Red Cross, Westmoreland County Chapter, Greensburg, Pennsylvania
1992-2005 Associate Professor, Department of Pharmaceutical Sciences, University of Pittsburgh
School of Pharmacy, Pittsburgh, Pennsylvania
1996-2005 Assistant Dean for Managed Care,
University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania
2000 Executive Vice President of Business Development and Chief Clinical Officer
CVS ProCare, a subsidiary of CVS/pharmacy, Inc., Pittsburgh, Pennsylvania
1998-2000 Executive Vice President of Business Development and Chief Clinical Officer
Bergen Brunswig Specialty Healthcare/Stadtlander Operating Co., LLC
Pittsburgh, Pennsylvania
1996-2000 Residency Director, Specialized Residency in Managed Care, University of
Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania
1999 Executive Vice President of Operations (interim), Stadtlanders Operating Company,
LLC, Pittsburgh, Pennsylvania

Gordon J. Vanscoy
Page 2
1997-1998 Executive Vice President, Managed Health Care and Sales, Stadtlanders Pharmacy,
Pittsburgh, Pennsylvania
1995-1997 Vice President, Clinical Care Division Stadtlanders Pharmacy, Pittsburgh, Pennsylvania
1993-1996 Vice Chairman, Department of Pharmacy and Therapeutics, University of Pittsburgh
School of Pharmacy, Pittsburgh, Pennsylvania
1991-1996 Residency Director, Specialized Residency in Drug Information (ASHP accredited),
University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania
1990-1995 Director, Drug Information and Pharmacoepidemiology Center, University of Pittsburgh
Medical Center (UPMC), Pittsburgh, Pennsylvania
1993-1995 Member, Center for Clinical Pharmacology, UPMC, Pittsburgh, Pennsylvania
1989-1995 Editor-in-Chief, Pharmacy Consult, Drug Information and Pharmacoepidemiology
Center, UPMC, Pittsburgh, Pennsylvania
1993 Interim Director, Office of Continuing Education, Department of Pharmacy and
Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania
1986-1992 Assistant Professor, Department of Pharmacy and Therapeutics, University of Pittsburgh
School of Pharmacy, Pittsburgh, Pennsylvania
1986-1990 Clinical Pharmacy Specialist: Ambulatory Care, Department of Veterans Affairs Medical
Center, Pittsburgh, Pennsylvania
1986-1990 Coordinator, Drug Information Resource Center, Department of Pharmacy and
Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania
OTHER:
2004- Executive Consultant, University of Pittsburgh Medical Center Health Plan, Pittsburgh,
Pennsylvania
1990-2005 Consulting Director, Anticoagulation Clinic Services, VA Health Care System,
Pittsburgh, Pennsylvania
1993-1995 Member, Express Pharmacy Services Medical Advisory Board, Pittsburgh, Pennsylvania
1986-1993 Sterile Products Pharmacist (casual), The Mercy Hospital, Pittsburgh, Pennsylvania
1984-1986 Pharmacist, Ayres Pharmacy, McKeesport, Pennsylvania
1984 Pharmacist, Thrift Drug Inc., North Huntingdon, Pennsylvania

Gordon J. Vanscoy
Page 3
LICENSURE/PRIVILEGES
1987- Category 1 Medication Prescribing Privileges, VA Pittsburgh Healthcare System
1984- Pennsylvania, RP-033773-L
HONORS AND AWARDS
2005 AMCP National P&T Competition. Second Place awarded to the University of
Pittsburgh AMCP Student Chapter (faculty advisor)
2004 Ernst & Young Entrepreneur of the Year Award (finalist). Western Pennsylvania
Region
2002 National Leadership Award. Republican Congressional Committee. Business Advisory
Council
2002 AMCP National P&T Competition. First Place awarded to the University of Pittsburgh
AMCP Student Chapter (faculty advisor)
2002 AMCP Spirit of Volunteerism Award Grant provided to the University of Pittsburgh
AMCP Student Chapter (faculty advisor) by recipient Darlene Mednick
1997 Academic Research Enhancement Award. Department of Health and Human Services
1997 Best Book: Drug Information. Doody’s Rating Service: A Buyer’s Guide to the 250
Best Health Science Books
1990 Beta Gamma Sigma Honor Society for collegiate schools of business
1988 Smith Kline & French Laboratories Investigators Award
1988 University Association for Emergency Medicine Best Scientific Paper Award
1987 Smith Kline & French Laboratories Young Investigators Award
1986 Bristol Award for outstanding achievement and personal contribution
1986 Outstanding Young Men of America
1984 Summa Cum Laude, B.S. Pharmacy, University of Pittsburgh
1984 Galen Award for outstanding achievement in medicinal biochemistry
1984 Burhenn Award for outstanding overall academic achievement
1984 Darbaker Scholarship
1983 Rho Chi Pharmaceutical Honor Society

Gordon J. Vanscoy
Page 4
MEMBERSHIPS IN PROFESSIONAL AND SCIENTIFIC SOCIETIES
1997- International Society of Pharmacoeconomics and Outcomes Research
1995- Academy of Managed Care Pharmacy
1995- American Pharmaceutical Association
1990- Three Rivers College of Clinical Pharmacy
1986- American College of Clinical Pharmacy
1986- American Association of Colleges of Pharmacy
1984- American Society of Health-System Pharmacists
1984- Pennsylvania Society of Health-System Pharmacists
1984- Western Pennsylvania Society of Health-System Pharmacists
1983- Rho Chi Pharmaceutical Honor Society
2000-2004 Society for Critical Care Medicine
1995-2000 Pharmaceutical Care Management Association
1994-2000 Allegheny Coagulation Optimization Group
1995-1997 Association for Pharmacoeconomics and Outcomes Research
1994-1997 Consortium for the Advancement of Medication Information, Policy and Research
1989-1997 Drug Information Association
1989-1995 International Society of Pharmacoepidemiology
1988-1992 American Academy of Clinical Toxicology
TEACHING RESPONSIBILITIES
UNIVERSITY OF PITTSBURGH, 1986 - present*
Graduate
Pharm 5211: Profession of Pharmacy 4: Business, Leadership and Entrepreneurs*
Pharm 5401: Advanced Pharmacy Practice Experiential*

Gordon J. Vanscoy
Page 5
Undergraduate
Pharm 5311: Profession of Pharmacy 6 (course co-coordinator)
Pharm 5400: Doctor of Pharmacy Seminar
Pharm 3402: Advanced Pharmacotherapy
ISSP 2015: Introduction to Medical Informatics
Pharm 3026: Pharmaceutical Literature Review
HRS 3237: Health Care Supervision/Management Administrative Internship
Student: Tracy Wang
Term: Summer
Year: 1996
Pharm 1410: Pharmacy and the Communications Process
Pharm 1501: Clinical Pharmacy Clerkship (course signature)
Pharm 1511: Community Pharmacy Externship (course signature)
Pharm 1512: Institutional Pharmacy Externship (course signature)
Pharm 1790: Undergraduate Research
Student: Stephanie Dern, Jill Pfeiffer, Angela Metzger, Jennette McVey
Project: Implementation of IRxBase: An Investigational Drug Information Database
Term: Winter
Year: 1995
Pharm 1790: Undergraduate Research
Student: Margaret M. Verrico
Project: Computer Support in the Diagnosis of Drug-Induced Disease: Phenytoin
Toxicity
Term: Winter
Year: 1992
CAS 0001: Freshman Studies I
Pharm 5100: Profession of Pharmacy
Team Taught Undergraduate Courses
Pharm 1400: Medication Information and Literature Evaluation
(course signature/coordinator)
Pharm Year: Fourth Year
Pharm 1490: Contemporary Pharmacy Practice
Pharm Year: Fourth Year

Gordon J. Vanscoy
Page 6
Course Development
Program Development
Pharm 0140: Foundations of Pharmacy Practice
Pharm Year: Fourth Year
Pharm 0153: Disease Management
Pharm Year: Fourth Year
Pharm 5211: Profession of Pharmacy 4 (business content coordinator)
Pharm 1400: Medication Information and Literature Evaluation
(course signature/coordinator)
Pharm 1501: Clinical Pharmacy Clerkship (course signature)
Pharm 1511: Community Pharmacy Externship (course signature)
Pharm 1512: Institutional Pharmacy Externship (course signature)
Pharm 3100: Advanced Pharmacotherapy
Pharm 5311: Profession of Pharmacy 6 (course co-coordinator)
Pharm 5211: Profession of Pharmacy 4: Business Management*
Residency Program Director/Preceptor: Pharmacy
Name: Erin Conley, Pharm.D.
Residency: Advanced Managed Care
Faculty role: Residency Director
Dates: July 1, 1999 through June 30, 2000
Name: Pamela Koerner, Pharm.D.
Residency: Advanced Managed Care
Faculty role: Residency Director
Dates: July 1, 1999 through June 30, 2000
Name: Pallav Raval, Pharm.D.
Residency: Advanced Managed Care
Faculty role: Residency Director
Dates: July 1, 1998 through June 30, 1999
Name: Anna Peris, Pharm.D.
Residency: Advanced Managed Care
Faculty role: Residency Director

Gordon J. Vanscoy
Page 7
Dates: July 1, 1998 through June 30, 1999
Name: JeanAh Choi, Pharm.D.
Residency: Drug Information, Managed Care Rotation
Faculty role: Preceptor
Dates: February 10, 1998 through March 13, 1998
Name: Brenda Castiglione, Pharm.D.
Residency: Advanced Managed Care
Faculty role: Residency Director
Dates: June 1, 1997 through May 31, 1998
Name: Christine Ritzman, Pharm.D.
Residency: Advanced Managed Care
Faculty role: Residency Director
Dates: August 1, 1996 through July 31, 1997
Name: Kathlene Melbourne, Pharm.D.
Residency: Pharmacy Practice
Faculty role: Preceptor for Managed Care
Dates: May 24, 1996 through June 21, 1996
Name: Andrea Ho-Kean, Pharm.D.
Residency: Drug Information Practice
Faculty role: Residency Director & Preceptor
Dates: August 1, 1995 through July 31, 1996
Name: Michelle McCarthy, Pharm.D.
Residency: Drug Information Practice
Faculty role: Residency Director & Preceptor
Dates: September 1, 1994 through August 31, 1995
Name: Ushma Mehta, Pharm.D.
Residency: Drug Information Practice
Faculty role: Residency Director & Preceptor
Dates: August 1, 1994 through July 31, 1995
Name: Lidia Gajewski, Pharm.D.
Residency: Drug Information Practice
Faculty role: Residency Director & Preceptor
Dates: August 1, 1993 through July 31, 1994
Name: Simone Baikovitz, Pharm.D.
Residency: Drug Information - The Mercy Hospital of Pittsburgh
Faculty role: Preceptor - Drug Information Mini-Rotation
Dates: March 30, 1994 through March 31, 1994

Gordon J. Vanscoy
Page 8
Name: Patrick A. Kelly, Pharm.D.
Residency: Pharmacy Practice
Faculty role: Preceptor - Drug Information
Dates: September 2, 1993 through October 1, 1993
Name: Michael G. Kendrach, Pharm.D.
Residency: Drug Information Practice
Faculty role: Residency Director & Preceptor
Dates: July 1, 1992 through June 30, 1993
Name: Sujata Kapai, Pharm.D.
Residency: Geriatrics
Faculty role: Preceptor - Ambulatory Care/Anticoagulation
Dates: March 1, 1993 through April 2, 1993
Name: Sujata Kapai, Pharm.D.
Residency: Geriatrics
Faculty role: Preceptor - Drug Information
Dates: February 1, 1993 through February 26, 1993
Name: Lauren Trilli-Vidic, Pharm.D.
Residency: General Clinical
Faculty role: Preceptor - Ambulatory Care/Anticoagulation
Dates: November 4, 1992 through January 29, 1993
Name: Lauren Trilli-Vidic, Pharm.D.
Residency: General Clinical
Faculty role: Preceptor - Drug Information
Dates: October 5, 1992 through November 1, 1992
Name: John Schlicht, Pharm.D., M.B.A.
Residency: Drug Information Practice
Faculty role: Residency Director & Preceptor
Dates: July 1, 1991 through June 30, 1992
Name: Charles Fetrow, Pharm.D.
Residency: General Clinical
Faculty role: Preceptor - Ambulatory Care/Anticoagulation
Dates: April 1, 1992 through June 3, 1992
Name: Charles Fetrow, Pharm.D.
Residency: General Clinical
Faculty role: Preceptor - Drug Information
Dates: August 1, 1991 through September 6, 1991
Mini-Rotation Director/Preceptor: Pharmacy

Gordon J. Vanscoy
Page 9
Name(s): Wendy Hutson, Nancy Spivey, Jodie Papin, Lonnye Finneman
Programs(s): Greater Baltimore Medical Center (Baltimore, MD), Tuomey Healthcare
System (Sumpter, SC), Brackenridge Hospital (Austin, TX, Southwest
Washington Medical Center (Vancouver, WA)
Faculty Role: Preceptor - ASHP Anticoagulation Traineeship
Dates: April 29, 2002 through May 3, 2002
Name(s): Scott Howard, Sandra Bardas, Biljana Popovic, Anita Wallace
Programs(s): Mt. Carmel East Hospital (Columbus, OH), Stanford Hospital/Clinics
(Stanford, CA), Harper University Hospital (Detroit, MI), Central
Alabama VA Healthcare System (Dothan, AL)
Faculty Role: Preceptor - ASHP Anticoagulation Traineeship
Dates: May 7, 2001 through May 11, 2001
Name(s): Lisa Ramos, Ken Gagnon, Prashant Patel, Glenn Laird
Programs(s): UC Davis Medical Center (Sacramento, CA), Ashley Valley Medical
Center (Vernal, UT), St. Francis Hospital/Medical Center (Hartford, CT),
Andrews Airforce Base (Andrews AFB, MD)
Faculty Role: Preceptor - ASHP Anticoagulation Traineeship
Dates: April 24, 2000 through April 28, 2000
Name(s): Clarissa Staley, Laura Veltri, Charles Dayton, Paige Akers
Programs(s): Rush-Presbyterian/St. Luke’s (Chicago, IL), Missouri Baptist Medical
Center (St. Louis, MO), University of Iowa Hospitals and Clinics, (Iowa
City, IA), Children’s Hospital Medical Center (Cincinnati, OH)
Faculty Role: Preceptor - ASHP Anticoagulation Traineeship
Dates: April 27, 1999 through April 30, 1999
Name(s): Shirley Wen, Andrew Neather, Ronald Baars, Patricia Jenkins
Programs(s): VAMC (West Los Angeles, CA), Not-Tsoo-Galt-Nee Indian Health
Center (Idaho, ID), N Colorado Medical Center (Greenly, CO), Tucson
Medical Center (Tucson, AZ)
Faculty Role: Preceptor - ASHP Anticoagulation Traineeship
Date: April 27, 1998 through April 30, 1998
Name(s): Sumana Alex, Renee Roncone, Stephen Foster, Jennifer Swanson
Program(s): ASCO Healthcare Inc., Phoenix Indian Health Center, Indian Health
Service, Blackfeet IHS Community Hospital
Faculty role: Preceptor - ASHP Anticoagulation Traineeship
Dates: April 28, 1997 through May 2, 1997
Name(s): Jennifer Bolding, Katherine Fonken, Richard Artymonicz, Melanie Joy
Programs: Overton Brooks VAMC, Austin VAMC, Burdette Tomlin Memorial
Hospital, Cabarrus Memorial Hospital
Faculty role: Preceptor - ASHP Anticoagulation Traineeship
Dates: October 21, 1996 through October 25, 1996
Name(s): Beth Prendergrast, Ron DeCostro
Date(s): The Medical Center, Beaver, PA

Gordon J. Vanscoy
Page 10
Faculty role: Preceptor - Anticoagulation Mini-Rotation
Dates: August 13, 1996 through August 14, 1996
Name: Mike McGuire
Program: The Germantown Hospital and Medical Center, Philadelphia, PA
Faculty role: Preceptor - Anticoagulation Mini-Rotation
Dates: April 9, 1996 through April 10, 1996
Name(s): Ed Curtin, Vivien Ng
Program: Pharma-Care, Inc., NJ
Faculty role: Preceptor - Anticoagulation Mini-Rotation
Dates: March 26, 1996 through March 27, 1996
Name(s): Kellie Cotter, Sandy Johnson, Jane Homes, Pat Lang
Program(s): Sparrow Hospital, William Backus Hospital, Allegheny Valley
Hospital, Lee Memorial Hospital
Faculty role: Preceptor - ASHP Anticoagulation Traineeship
Dates: October 23, 1995 through October 27, 1995
Name(s): Pete Lempke, Doug Joseph
Program: Vitalink Pharmacy Services, Allentown, PA
Faculty role: Preceptor - Anticoagulation Mini-Rotation
Dates: June 13, 1995 through June 14, 1995
Name: Linda Bitondo
Program: Graduate Hospital, Philadelphia, PA
Faculty role: Preceptor - Anticoagulation Mini-Rotation
Dates: November 29, 1994 through November 30, 1994
Name(s): Omar Shoheiber, Cindy Yuen
Residency: Pharmacy Practice - Hospital of the University of Pennsylvania,
Philadelphia, PA
Faculty role: Preceptor - Anticoagulation Mini-Rotation
Dates: March 8, 1994 through March 9, 1994
Name: Nick Brabander
Residency: Pharmacy Practice - Geisinger Medical Center, Danville, PA
Faculty role: Preceptor - Anticoagulation Mini-Rotation
Dates: September 28, 1993 through September 29, 1993
Name: Earl L. Marble
Program: Syracuse VAMC Clinical Coordinator, NY
Faculty role: Preceptor - Anticoagulation Mini-Rotation
Dates: July 20, 1993 through July 21, 1993

Gordon J. Vanscoy
Page 11
Name: David Laufer
Residency: Pharmacy Practice - Hospital of the University of Pennsylvania,
Philadelphia, PA
Faculty role: Preceptor - Anticoagulation Mini-Rotation
Dates: February 16, 1993 through February 17, 1993
Residency Mini-Rotation Director/Preceptor: Medicine
Name: Christopher T. Addis, MD
Position: Internal Medicine - Internal Medicine of Lancaster
Faculty role: Preceptor - Anticoagulation Mini-Rotation
Dates: August 19, 1997 through August 20, 1997
Name: Aurora Mandanguit, M.D.
Residency: Primary Care - St. Francis Health System, Pittsburgh, PA
Faculty role: Preceptor - Anticoagulation Mini-Rotation
Dates: August 13, 1996 through August 14, 1996
Name: Lucia A. Garino, M.D.
Residency: Internal Medicine - The Medical College of Pennsylvania,
Philadelphia, PA
Faculty role: Preceptor - Anticoagulation Mini-Rotation
Dates: April 9, 1996 through April 10, 1996
Name(s): Lawrence Chua, M.D., Shashikala Sarma, M.D.,
Ramesh Thimmiah, M.D.
Residency: Internal Medicine - St. Francis Medical Center, Pittsburgh, PA
Faculty role: Preceptor - Anticoagulation Mini-Rotation
Dates: January 10, 1995 through January 11, 1995
Name: William Langhorne, M.D.
Residency: Cardiology - Cardiology Consultants, Pensacola, FL
Faculty role: Preceptor - Anticoagulation Mini-Rotation
Dates: November 23, 1994 through November 24, 1994
Name: Saeed UrRahman, M.D.
Residency: Internal Medicine - West Penn Hospital, Pittsburgh, PA
Faculty role: Preceptor - Anticoagulation Mini-Rotation
Dates: February 15, 1994 through February 16, 1994
Name: David Schafer, M.D.
Residency: Hematology - York Hospital, York, PA
Faculty role: Preceptor - Anticoagulation Mini-Rotation
Dates: October 23, 1994 through October 24, 1994
Name(s): Jieuken Lou, M.D., Suresh Nellore, M.D.,
Maralidhar Santapuram, M.D
Residency: Internal Medicine - Luthern Medical Center, Cleveland, OH

Gordon J. Vanscoy
Page 12
Faculty role: Preceptor - Anticoagulation Mini-Rotation
Dates: October 13, 1994 through October 14, 1994
Name: Juan Cabanero, M.D.
Residency: Internal Medicine - Shadyside Hospital, Pittsburgh, PA
Faculty role: Preceptor - Anticoagulation Mini-Rotation
Dates: October 13, 1994 through October 14, 1994
Name: Ibrahim Abdalla, M.D.
Residency: Internal Medicine - Luthern Medical Center, Cleveland, OH
Faculty role: Preceptor - Anticoagulation Mini-Rotation
Dates: February 2, 1993 through February 3, 1993
Name(s): Christina Sadowsky, M.D., Hosam Sayed, M.D.
Residency: Internal Medicine - Meridia Huron Hospital, Cleveland, OH
Faculty role: Preceptor - Anticoagulation Mini-Rotation
Dates: January 19, 1993 through January 20, 1993
Name: George Partal, M.D.
Residency: Internal Medicine - Luthern Medical Center, Cleveland, OH
Faculty role: Preceptor - Anticoagulation Mini-Rotation
Dates: October 26, 1992 through October 27, 1992
Name: Adnan Sammour, M.D.
Residency: Internal Medicine - Scranton Temple Residency, PA
Faculty role: Preceptor - Anticoagulation Mini-Rotation
Dates: October 13, 1992 through October 14, 1992
Name(s): Bernard Chinnasami, M.D., Manuel Puerta, M.D.
Residency: Internal Medicine - Polyclinic
Faculty role: Preceptor - Anticoagulation Mini-Rotation
Dates: May 26, 1992 through May 27, 1992
Mini-Rotation Director/Preceptor: Nursing
Name: Susan Daunch, C.R.N.P., M.S.N., R.N.
Program: The Cleveland Clinic, Cleveland, OH
Faculty role: Preceptor - Anticoagulation Mini-Rotation
Dates: October 3, 1995 through October 4, 1995
Name: Debra Hilty, C.R.N.P.
Program: Benedum Geriatric Center, WPIC, Pittsburgh, PA
Faculty role: Preceptor - Anticoagulation Mini-Rotation
Dates: November 29, 1994 through November 30, 1994
Name: Miriam Serrate, R.N.
Program: CAC Ramsay Health Plans, Coral Gables, Florida
Faculty role: Preceptor - Anticoagulation Mini-Rotation

Gordon J. Vanscoy
Page 13
COMMITTEES:
BUSINESS/POLITICS
Dates: August 23, 1994 through August 24, 1994
Name: Cindy A. Wojtecki, R.N.
Program: Syracuse VAMC, Syracuse, NY
Faculty role: Preceptor - Anticoagulation Mini-Rotation
Dates: July 20, 1993 through July 21, 1993
Name(s): Leah Alford, R.N., Sandra Rohan, R.N., Martha Nealy, R.N.
Program: Cardiology Consultants, Pensacola, FL
Faculty role: Preceptor - Anticoagulation Mini-Rotation
Dates: November 23, 1993 through November 24, 1993
Name: Jane Pond, M.S.N., C.R.N.P.
Program: Hospital of the University of Pennsylvania, Philadelphia, PA
Faculty role: Preceptor - Anticoagulation Mini-Rotation
Dates: February 16, 1993 through February 17, 1993
SERVICE
National Republican Congressional Committee, Business Advisory Council
2006- Business Advisory Council (member, Pennsylvania)
2002-2005 Business Advisory Council (honorary chairman, Pennsylvania)
HUMANITARIAN
American Red Cross, Westmoreland County Chapter
2006- Board of Directors (chairman)
2006- Board of Directors Executive Committee (chairman)
2006 Board of Directors (vice chairman)
2006- Board of Directors Development, Nominating, and Community Committee (chairman)
2006 Board of Directors Executive Committee (member)
2005 Board of Directors (member)
PROFESSIONAL ORGANIZATIONS
American Association of Colleges of Pharmacy (AACP)

Gordon J. Vanscoy
Page 14
2004-2005 Joint/Combined Degree Taskforce of the Councils of Deans and Faculties
Academy of Managed Care Pharmacy (AMCP)
1998-2005 University of Pittsburgh AMCP Student Chapter (founder, faculty advisor)
1996-2005 Diplomat/Ambassador Program (faculty representative)
1999-2002 Framework for Drug Therapy Management in the 21 st Century (member)
1997-1998 Legislative Committee (member)
1996-1998 Professional Practice Committee, Residency Task Force (member)
1996-1997 Educational Affairs Committee (member)
Allegheny Coagulation Optimization Group (ACOAG)
1994-1997 Founding President (member)
American Association of Colleges of Pharmacy (AACP)
1993-1998 Section on Continuing Pharmaceutical Education Ethics Committee (member)
American Council on Pharmaceutical Education (ACPE)
2000- ACPE Provider Advisory Committee (member)
Accreditation Council for Pharmacy Education (ASHP)
2000 Residency Accreditation Survey Team, Managed Care, Walgreens Health Initiative
(member)
1998 Pharmacy in Managed Care: Vision for the Future Conference (nominating committee)
1994-1998 Section of Clinical Specialists, Committee on Academia (member)
1996 Residency Accreditation Survey Team, Drug Information Practice, Temple
University Hospital, (member)
1992-1994 Specialty Practice Group in Drug Information (SPG-DI) Education
Programming Committee (member)
1992-1994 SPG-DI Specialty Residency Standards Committee (member)
1992-1993 SPG-DI Research Forum Committee (1992 chairman and founder)
1993 SPG-DI (chairman)

Gordon J. Vanscoy
Page 15
1992 SPG-DI (vice chairman)
Consortium for the Advancement of Medication Information, Policy & Research (CAMIPR)
1994-1997 Founding Executive Director
International Society of Pharmacoeconomics and Outcomes Research (ISPOR)
1998-2000 Board of Directors (member)
National Certified Anticoagulation Care Providers (CACP)
1998-2005 Board of Directors (member)
1996-1998 Founding Chairman
Pharmaceutical Care Management Association (PCMA)
1998-1999 Quality Measures Committee (member)
1996-1998 Pharmaceutical Outcomes Research Standards Committee (chairman)
Three Rivers College of Clinical Pharmacy (TRCCP)
1992 Nominations Committee (member)
University Hospital Consortium (UHC)
1994-1995 Clinical Value Management Committee (member)
1991-1993 Drug Information Network Steering Committee (member)
United States Pharmacopeia (USP)
1995-2000 Therapeutic Information Management Advisory Panel 1995-2000 (member)
UNIVERSITY AND SCHOOL
2005-2006 Schools of the Health Science Winter Academy (host committee member)
2005-2006 Search Committee: Associate Dean for Education - Dr. Susan Meyer (member)
1996- Dean’s Executive Leadership Committee; School of Pharmacy (member)
1996- Joseph M. Katz Graduate School of Business Alumni Admission Council (member)
2002-2005 School of Pharmacy Efficiency & Effectiveness Council (member)
1992-2005 Pharmaceutical Continuing Education Steering Committee (member)

Gordon J. Vanscoy
Page 16
2001-2003 Clinical Service Partnership Strategic Planning Group (chairman)
2001-2003 Residency Strategic Planning Group (chairman)
2001-2003 Financial Strategic Planning Group (member)
1996-2001 International Smoking Cessation Specialist Certification Program Advisory Board
(chairman)
1992-2001 Residency Committee; School of Pharmacy (member)
2000 National Consensus Panel on the Therapeutic Interchange of Low-Molecular Weight
Heparins (chairman)
1999-2000 University Health Promotions Leadership Committee (member)
1995-1998 The University Senate; The Faculty Assembly; The University of Pittsburgh
(elected representative)
1986-1997 Medication Information and Literature Evaluation Course Development
Committee; School of Pharmacy (chairman)
1996-1997 Grievance Panel; University of Pittsburgh (Provost-appointed member)
1996-1997 Search Committees: Outcomes/Experiential Education Coordinator- Dr. Patrick
Gleason (member); Drug Information Director- Dr. Jill Brufsky (member);
Drug Information Specialist- Dr. Jodi Sullivan (member)
1996-1997 ACPE School Accreditation Self-Study Subcommittee (member)
1996-1997 ACPE CE Accreditation Committee (co-chairman)
1994-1996 Experiential Education Steering Committee (chairman)
1993-1996 Budget Committee; Department of Pharmacy and Therapeutics (member)
1992-1996 Executive Committee; Department of Pharmacy and Therapeutics (vice chair)
1990-1995 Pharmacy Consult Editorial Board (editor-in-chief)
1986-1995 Curriculum Committee; School of Pharmacy (member)
1995 Search Committee; VA Clinical Pharmacy Specialist - Dr. Lauren Trilli
(member)
1994-1995 University of Pittsburgh Task Force on the Management of Scientific &
Technical Information (Chancellor appointed member)
1993-1995 Doctor of Pharmacy Steering Committee (member)

Gordon J. Vanscoy
Page 17
1994 Search Committee; Experiential Education Coordinator (member)
1994 Promotion Committee - Dr. Carol Myers (member)
1994 Search Committee; Drug Information Specialist - Dr. Lidia Gajewski (chairman)
1993 Search Committee; Public Health Faculty - Dr. Grace Lamson (member)
1993 School of Pharmacy Curriculum Reconstruction Team 1 (member)
1989-1993 Search Committee; Pharmacoepidemiologist - Dr. Carlene Baum (chairman)
1992-1993 Doctor of Pharmacy Admissions Committee; Department of Pharmacy and Therapeutics
(member)
1990-1993 Pharmacy Administration Curriculum Committee Task Force; School of Pharmacy
(chairman)
1990-1993 Western Pennsylvania Society of Hospital Pharmacists; School of Pharmacy (school
representative)
1989-1993 Drug Information and Pharmacy Committee (chairman)
1992 Budget Committee; School of Pharmacy (member)
1992 Search Committee; Assistant Director of Western Psychiatric Institute and Clinic
Pharmacy (member)
1991-1992 Academic Integrity Committee; School of Pharmacy (member)
1991-1992 Doctor of Pharmacy Admission Materials Subcommittee; Department of Pharmacy and
Therapeutics (chairman)
1989-1992 Search Committee; Drug Information Specialists (chairman)
1990-1991 ACPE Accreditation Self-Study Subcommittee on Educational Resources (member)
1986-1987 Academic Integrity Committee (member)
STADTSOLUTIONS, L.L.C.
1998 Board of Directors (member)
STADTLANDERS/ASD
1999-2000 Internet Strategy Committee (member)
1999-2000 National Transplant Disease Management and Formulary Committee (chairman)

Gordon J. Vanscoy
Page 18
1998-2000 National Serious Mental Illness Disease Management and Formulary Committee
(chairman)
1998-2000 National Corrections Disease Management and Formulary Committee (member)
1998-2000 Executive Management Group (member)
1997-2000 National HIV Disease Management and Formulary Committee (chairman)
1997-1998 National Neurology Disease Management and Formulary Committee (chairman)
1995-1998 Senior Management Group (member)
1995-1997 StadtCare Clinician Editorial Board (member)
HEALTH SYSTEM (UPMC)
1996 Biomedical Institutional Review Board (alternate member)
1995-1996 Investigation Drug-Related Morbidity Committee; Biomedical
Institutional Review Board (founding chair)
1995-1996 Clinical Pathway Task Force; DVT/PE (member)
1995 Formulary Committee (founding chair)
1994-1995 Drug-Related Morbidity Committee (chair)
1993-1995 Biomedical Institutional Review Board (member, acting vice-chair
October, 1994)
1993-1995 Pharmaceutical Industry Committee (member)
1991-1995 Pharmacy and Therapeutics Committee (member)
1991-1995 Drug Advisory Program Steering Committee (member)
1994-1995 Pharmacy Steering Committee (member)
1994-1995 Search Committee; Investigational Drug Director (member)
1994-1995 Center for Clinical Pharmacology (member)
1993 Drug Expense Reduction Committee (member)
1991-1993 Pharmacy Directors Group (member)

Gordon J. Vanscoy
Page 19
1990-1993 Pharmacy and Therapeutics Committee; Western Psychiatric Institute and Clinic
(member)
1990-1993 Pharmacy Computer Committee (member)
1990-1991 Drug Use Evaluation Subcommittee (member)
1990-1991 Adverse Drug Reaction Subcommittee (member)
1990-1991 Pharmacy and Therapeutics Committee; Presbyterian University Hospital (member)
1990-1991 Pharmacy and Therapeutics Committee; Montefiore University Hospital (ex-officio)
1986-1990 Pharmacy and Therapeutics Committee; Department of Veterans Affairs Medical Center
(member)
CONSULTANT
1996- Chesapeake Research Review, Inc., Biomedical Institutional Review Board (member)
1990-2005 Anticoagulation Clinic Services, Pittsburgh Veterans Affairs Health System (director)
2001 Lovenox ® Closed Consultants Meetings, Aventis Pharmaceuticals (faculty)
1999 Roche UK Influenza Advisory Board (member)
1998-1999 Bayer Partners in Pharmacy Education Advisory Council (member)
1997-1998 Integrelin ® National Pharmacy Advisory Panel (member)
1996 Coumadin ® Pharmacy Advisory Board, Dupont - Merck Pharmaceuticals (chairman)
1996 Invirase ® Pharmacy Advisory Board, Roche Laboratories (member)
1994-1995 Stadtlanders Drug Co. Managed Pharmaceutical Care Initiative
1992-1995 Thrift Drug Inc., "Ask our Pharmacist" Drug Information/Compliance Center
1993-1995 Express Pharmacy Services, Thrift Drug, Inc. Medical Advisory Board
REVIEWER
Journal Reviewer:
2005- American Journal Cardiology
2004- American Journal of Managed Care (relevance review)
2003- Drugs

Gordon J. Vanscoy
Page 20
1993- Annals of Pharmacotherapy
1992- Hospital Pharmacy
1997-2001 Drug Benefit Trends
Editorial Board(s):
2006- American Journal of Oncology Review, TyWin Communications
2004- Cancer Support Innovation, University Pharmacotherapy Associates, L.L.C.,
(editor-in-chief)
2001- Value in Thrombosis Management, University Pharmacotherapy Associates, L.L.C.,
(editor-in-chief)
1997- Journal of Thrombosis and Thrombolysis, Section Editor, Kluwer Academic Publishers
1996- Horizons in Fibrinolysis, University of Pittsburgh (editor-in-chief)
1995- Drug Formulary Review, American Health Consultants
1995- New Frontiers in Antithrombosis, University Pharmacotherapy Associates, L.L.C.,
(editor-in-chief)
1991- Drugdex Computerized Clinical Information Service
2000-2001 Horizons in Antithrombosis, University Pharmacotherapy Associates, L.L.C., (editor-in
chief)
1997-2001 National Smoking Cessation Newsletter, University of Pittsburgh
1995-2000 Lifetimes, Stadtlander Drug Co., Inc.
1995-1998 Stedman’s WordWatcher, Williams & Wilkins
1992-1996 ETSAMI Update, University of Pittsburgh (editor-in-chief)
1991-1995 UHC Drug Monographs
1990-1995 Pharmacy Consult (editor-in-chief)
1993-1995 Express Pharmacy Services Comparative Drug Monographs (editor-in-chief)
1991-1995 UPMC Pharmagram (editor-in-chief)
1990-1993 Rx Update (editor-in-chief)

Gordon J. Vanscoy
Page 21
INVITED LECTURES
PRESENTATIONS
Clinical application of non-steroidal anti-inflammatory drugs. Mid-Atlantic College Health Association
Meeting. Somerset, Pennsylvania. 1988.
Development and management of a multi-disciplinary anticoagulation clinic. Anticoagulation Therapy
Update, Veterans Affairs Hospital. Indianapolis, Indiana. 1988.
Cimetidine use in Amanita Phalloides poisoning: mechanism of hepatoprotection. American Society of
Hospital Pharmacists 22nd Midyear Clinical Meeting Exhibitors' Theater. Atlanta, Georgia. 1988.
Controversy in anticoagulant therapy: U.S./U.K. experience. Medical Grand Round, The Community
Hospital at Glen Cove. Glen Cove, New York. 1988.
A critical evaluation of flurbiprofen: Where does it fit into arthritis therapy? Upjohn Clinical Liaison
Conference. Boston, Massachusetts. 1989.
Experimental treatment modalities in the management of toxic mushroom ingestions. Gastroenterology
Grand Rounds, Presbyterian-University Hospital. Pittsburgh, Pennsylvania. 1989.
Drug information and pharmacoepidemiology. Medial Toxicology Grand Rounds, Montefiore University
Hospital. Pittsburgh, Pennsylvania. 1989.
Rational use of anticoagulants. Medical Grand Rounds, Altoona General Hospital. Altoona,
Pennsylvania. 1989.
Update on antithrombotics. Family Practice Clinical Rounds, St. Margaret Memorial Hospital.
Pittsburgh, Pennsylvania. 1990.
Treating non-valvular atrial fibrillation. Internal Medicine Grand Rounds, Forbes Regional Medical
Center. Monroeville, Pennsylvania. 1990.
Low-intensity anticoagulation. Medical Grand Rounds, West Virginia University Hospital. Morgantown,
West Virginia. 1990.
Second-generation thrombolytics. Medical Grand Rounds, Altoona General Hospital. Altoona,
Pennsylvania. 1990.
Pharmacokinetics/pharmacodynamics of warfarin. Clinical Pharmacy Rounds, Allegheny General
Hospital. Pittsburgh, Pennsylvania. 1990.
Treating non-valvular atrial fibrillation. Divine Providence Hospital Medical Rounds. Pittsburgh,
Pennsylvania. 1991.

Gordon J. Vanscoy
Page 22
Acute myocardial infarction: The role of adjuvant therapy. Greene County Memorial Hospital Medical
Education Series. Waynesburg, Pennsylvania. 1991.
Status of the open artery theory: GISSI-2, ISIS-3, and GUSTO. Latrobe Area Hospital Medical Grand
Rounds. Latrobe, Pennsylvania. 1992.
Mr. Bush's PT is 52? Three Rivers College of Clinical Pharmacy Meeting. Morgantown, West Virginia.
1992.
Survey and evaluation of newsletters marketed to family practice physicians. Twenty-fifth Annual Spring
Conference of the Society of Teachers of Family Medicine. St. Louis, Missouri. 1992.
Current trends in anticoagulation. Family Practice Educational Conference. West Virginia University.
Morgantown, West Virginia. 1992.
Computer support in diagnosis of drug-induced disease: Phenytoin toxicity. Fourteenth Annual
Undergraduate Research Seminar. Morgantown, West Virginia. October 9, 1992.
Assessing the impact of published standards on the treatment of atrial fibrillation. Fourteenth Annual
Undergraduate Research Seminar. Morgantown, West Virginia. October 9, 1992.
Anticoagulation workshop. Western Pennsylvania Society of Hospital Pharmacists Third Annual Clinical
Skills Seminar and Workshop, Allegheny General Hospital. Pittsburgh, Pennsylvania. October 23, 1992.
Polypharmacy in older adults. University of Pittsburgh Geriatric Lecture Series. Pittsburgh,
Pennsylvania. November 10, 1992.
Computer-assisted diagnosis of drug induced diseases. Twenty-seventh Annual ASHP Midyear Clinical
Meeting. Orlando, Florida. December 9, 1992.
Design and implementation of a multi-hospital staff development program in drug information at a
university medical center. Twenty-seventh Annual ASHP Midyear Clinical Meeting Orlando. Florida.
December 9, 1992.
Development of a LAN-based multi-institutional drug information database. Twenty-seventh Annual
ASHP Midyear Clinical Meeting. Orlando, Florida. December 9, 1992.
Current concepts in anticoagulation: ACCP recommendations. National Institutes of Health, Department
of Health and Human Services Educational Seminar Series. Bethesda, Maryland. January 13, 1993.
Current concepts in anticoagulation: ACCP recommendations. Latrobe Area Hospital Medical Education
Conference. Latrobe, Pennsylvania. February 20, 1993.
Anticoagulation in the 90's. North Hills Passavant Hospital Medical Education Program. Pittsburgh,
Pennsylvania. February 25, 1993.
Pharmacotherapy of AMI. Oklahoma Society of Hospital Pharmacists Annual Meeting. Oklahoma City,
Oklahoma. April 17, 1993.

Gordon J. Vanscoy
Page 23
Thrombolytics and adjunctive agents in AMI. Nebraska Society of Hospital Pharmacist Spring Seminar
1993. Omaha, Nebraska. May 1, 1993.
Treating AMI: Gusto and beyond. Illinois Society of Hospital Pharmacist Spring Seminar. Chicago,
Illinois. May 17, 1993.
Do's and don'ts of anticoagulant therapy. St. Francis Medical Center Grand Rounds. November 19,
1993.
Update on antithrombotic therapy. West Penn Hospital General Surgery Grand Rounds. November 10,
1993.
Drug informatics. 28th Annual ASHP Midyear Clinical Meeting. Atlanta, Georgia. December 8, 1993.
Paperless drug information center. Twenty-eighth Annual ASHP Midyear Clinical Meeting. Atlanta,
Georgia. December 8, 1993.
Residency portfolio: a tool for self-directed development. Twenty-eighth Annual ASHP Midyear Clinical
Meeting. Atlanta, Georgia. December 8, 1993.
Impacting acute myocardial infarction. Twenty-eighth Annual ASHP Midyear Clinical Meeting. Atlanta,
Georgia. December 9, 1993.
Global utilization of streptokinase and t-PA for occluded coronary arteries trial results and implications:
what now? Twenty-eighth Annual ASHP Midyear Clinical Meeting. Atlanta, Georgia. December 9,
1993.
Update on antithrombotic therapy. Allegheny Chapter of the Pennsylvania Academy of Family
Physicians Meeting. Pittsburgh, Pennsylvania. February 20, 1994.
Drug use and the elderly. Geriatric Emergencies. Passavant Hospital. Pittsburgh, Pennsylvania.
February 24, 1994.
Natural products and the athlete: fact and folklore. Western Pennsylvania Chapter of the Pennsylvania
Society of Hospital Pharmacists Meeting. Pittsburgh, Pennsylvania. March 17, 1994.
The evolution of drug informatics. Twenty-eighth Annual HPPMA/HSS Health Care Forum. Pittsburgh,
Pennsylvania. April 29, 1994.
Anticoagulant pharmacology. Harmarville Rehabilitation Center, Inc., PM&R Residency Lecture Series.
Pittsburgh, Pennsylvania. July 7, 1994.
Innovation in drug information. 1994 Annual Meeting of the American College of Clinical Pharmacy.
St. Louis, Missouri. August 1, 1994.
Networking drug information resources within an institution. 1994 Annual Meeting of the American
College of Clinical Pharmacy. St. Louis, Missouri. August 3, 1994.

Gordon J. Vanscoy
Page 24
New standards of practice in anticoagulation. Pennsylvania Society of Physician Assistants 19th Annual
Conference. State College, Pennsylvania. October 20, 1994.
Healthcare economics: A new tool for clinical decision-making. Maryland Society of Hospital
Pharmacists Meeting. University of Maryland. Baltimore, Maryland. November 10, 1994.
DVT prophylaxis. Harmarville Rehabilitation Center, Inc., PM&R Residency Lecture Series. Pittsburgh,
Pennsylvania. November 17, 1994.
Critical pathways approach to therapeutic management. University Hospital Consortium Pharmacy
Advisory Committee Annual Meeting. Miami, Florida. December 3, 1994.
The future of drug information: A CAMIPR perspective. Twenty-ninth Annual ASHP Midyear Clinical
Meeting. Miami, Florida. December 4, 1994.
Critical pathways: Pharmacotherapy of myocardial infarction. Twenty-ninth Annual ASHP Midyear
Clinical Meeting. Miami, Florida. December 8, 1994.
Pharmacy and the new managed care environment. Pittsburgh Managed Pharmaceutical Care
Conference. Pittsburgh, Pennsylvania. January 19, 1995.
Current standards in anticoagulation therapy. Medical Resident Pharmacology Rounds, Altoona General
Hospital. Altoona, Pennsylvania. February 10, 1995; Highland Drive Veterans Affairs Medical Center.
Pittsburgh, Pennsylvania. April 19, 1995; Shadyside Medical Center Department of Medicine;
Pittsburgh, Pennsylvania. April 24, 1995.
Critical pathways. University of Illinois at Chicago College of Pharmacy Invited Professorship Lecture.
Chicago, Illinois. March 30, 1995.
Integrating pharmacists into critical pathways. University of Illinois at Chicago College of Pharmacy
Invited Professorship Roundtable Discussion. Chicago, Illinois. March 30, 1995.
Development of an interactive electronic formulary. University Hospital Consortium Clinical Values
Management Committee Meeting. Chicago, Illinois. April 26, 1995.
Managing the pharmacy benefit of the high-risk, high-cost patient. Blue Cross and Blue Shield of
Western Pennsylvania Case Managers. Pittsburgh, Pennsylvania. August 8, 1995, and August 30, 1995.
Critical pathways to impacting outcomes. Kentucky Society of Health-System Pharmacists 1995 Annual
Meeting. Lexington, Kentucky. September 14, 1995.
Transplant medication compliance monitoring. Fujisawa, Inc. Chicago, Illinois. September 20, 1995.
How pharmacists can meet the challenges of health care reform and managed care. Samford University.
Birmingham, Alabama. November 2, 1995.
The future of drug information practice. Thirtieth Annual ASHP Midyear Clinical Meeting. Las Vegas,
Nevada. December 5, 1995.

Gordon J. Vanscoy
Page 25
Critical pathways to impacting outcomes: Pharmacotherapy of AMI. Tri-County West Virginia Medical
Society Meeting. Clarksburg, West Virginia. June 6, 1996.
Contemporary use of anticoagulation guidelines. Allegheny Family Practice Physicians of Altoona
Hospital. Altoona, Pennsylvania. June 17, 1996.
Controversies in the treatment of deep vein thrombosis. DuPont-Merck Pharma Regional Sales
Representative Meeting. Oglebay, West Virginia. July 30, 1996.
Oral anticoagulation: Improving the risk-benefit ratio. American Society of Consultant Pharmacists’
Third Annual Consultant Pharmacist Day in Pennsylvania. King of Prussia, Pennsylvania. October 10,
1996.
The role of pharmaceutical care programs in the quality equation: The medical-pharmacy challenge.
Understanding the Complexities of Managed Care: 1997 and Beyond. EMMG. Kansas City, Missouri.
October 22, 1996.
Clinical outcomes research standards: Disease management primer. American Managed Care Pharmacy
Association Annual Membership Meeting and Conference. San Antonio, Texas. October 27, 1996.
StadtRx: An intelligent disease management electronic prescribing system. Correction Corporation of
America Annual Health Supervisor Meeting. Nashville, Tennessee. February 9, 1997.
National smoking cessation specialist certification program. American Pharmaceutical Association
Annual Meeting. Los Angeles, California. March 10, 1997.
The role of pharmaceutical care programs in the quality equation: The medical-pharmacy challenge.
Integrating Outcomes & Disease Management into Pharmacy Strategies. Cambridge Health Resources.
Boston, Massachusetts. March 24, 1997.
Therapeutic frontiers in acute ischemic stroke. Alabama Society of Health-System Pharmacists Annual
Meeting. Huntsville, Alabama. April 25, 1997.
New frontiers in antiplatelet and anticoagulant therapy. Georgia Society of Health-System Pharmacists
Annual Meeting. Atlanta, Georgia. October 5, 1996; South-Eastern Society of Health-System
Pharmacists Annual Meeting. Huntsville, Alabama. April 25, 1997.
Treating HIV and AIDS: New drug profiles and clinical data - an evolving armanmentarium. Academy
of Managed Care Pharmacy Ninth Annual Meeting. New Orleans, Louisiana. May 9, 1997.
Innovations in residency programs in managed care pharmacy: The residency portfolio as a learning tool.
Academy of Managed Care Pharmacy Ninth Annual Meeting. New Orleans, Louisiana. May 10, 1997.
Credentialing of anticoagulation providers: A proposed model. The Anticoagulation Forum. San
Antonio, Texas. May 16, 1997.
Current standards of practice: Oral anticoagulation. Royal Counties’ Society of Hospital Pharmacists.
New York, New York. July 16, 1997.

Gordon J. Vanscoy
Page 26
Outpatient management of DVT. Thrombosis, Thrombolysis and Anticoagulation for the Clinician:
Guidelines for Safe and Effective Management in 1997; University of Massachusetts Medical Center.
Boston, Massachusetts. September 19, 1997.
Quality in HIV/AIDS managed pharmaceutical care. Medical Case Management Nineteenth Annual
Meeting. Nashville, Tennessee. September 30, 1997.
Uncomplicated proximal DVT. 1997 ACCP Annual Meeting. Phoenix, Arizona. November 11, 1997.
Strategies to manage HIV/AIDS drug-related dilemmas. Los Angeles Physicians AIDS Forum Meeting.
Beverly Hills, California. November 20, 1997.
Credentialing anticoagulation providers. Twelfth Annual Pharmacy Invitational Conference on
Anticoagulation. Atlanta, Georgia. December 6, 1997.
Managed care perspective on recent legislation. International Society Pharmacoeconomics and Outcomes
Research U.S. Legislative Briefing. Washington, D.C. January 6, 1998.
Building a synergy bridge from academia to managed care practice. Innovations in Pharmacy Practice.
AACP/Zeneca Academic Management Symposium. Savannah, Georgia. February 16, 1998.
Managed care partnerships breakout session. Innovations in Pharmacy Practice. AACP/Zeneca
Academic Management Symposium. Savannah, Georgia. February 16, 1998.
Basic considerations in anticoagulation therapy. Anticoagulation Therapy Update 1998. Henry Ford
Health System Heart and Vascular Institute. Dearborn, Michigan. April 29, 1998.
Anticoagulation therapy: Optimizing the risk-benefit ratio. New York City Society of Health System
Pharmacists. New York, New York. April 30, 1998.
Current standards of practice: Oral anticoagulation. Ashtabula County Medical Center Pharmacy and
Therapeutics Committee Meeting. Ashtabula, Ohio. May 8, 1998.
Appropriate anticoagulation. Virginia Academy of Family Physicians 50 th Annual Scientific Assembly.
Virginia Beach, Virginia. July 23, 1998.
Anticipating the new CHEST guidelines in anticoagulation. Allegheny Family Practice Physicians of
Altoona Hospital. Altoona, Pennsylvania. August 27, 1998.
1998 ACCP consensus conference on antithrombotic therapy update. Contemporary Approaches to
Anticoagulation Disorders. Wayne State University. Detroit, Michigan. March 24, 1999; Mid-Atlantic
College of Clinical Pharmacy Meeting. Philadelphia, Pennsylvania. April 22, 1999.
Pharmacoeconomics of the GP IIb/IIIa inhibitors. Cleveland Clinic Interventionist Update. Cleveland,
Ohio. June 5, 1999.
Innovative partnerships: Specialty pharmacy, academia, and the pharmaceutical industry. Managed Care
Partnerships: The Corporatization of Health Care and Its Impact on Companies and Patients. The Drug
Information Association. Philadelphia, Pennsylvania. September 12, 2000.

Gordon J. Vanscoy
Page 27
Scientific basis for therapeutic interchange: Results of the 2000 LMWH national consensus panel.
Methodist Health System Grand Rounds. San Antonio, Texas. May 11, 2001.
Administrative and ethical issues in the provision of continuing pharmaceutical education. ACPE 9th
Invitational Conference on Continuing Pharmaceutical Education. Phoenix, Arizona. November 3, 2001.
Scientific basis for therapeutic interchange: Results of the 2000 LMWH national consensus panel.
St. Vincent’s Medical Center Grand Rounds. Portland, Oregon. January 9, 2002; Lutheran Hospital
Grand Rounds. Fort Wayne, Indiana. March 12, 2002.
LMWH horizons: New uses, new evidence, new agents. New York-Presbyterian, The University
Hospital of Columbia and Cornell Pharmacy Grand Rounds. August 6, 2002. New York, New York.
How to effectively manage today’s formulary. Formulary Placement. Barnett International. Philadelphia,
Pennsylvania. November 15, 2002.
Improving strategies for formulary positioning. Formulary placement. Barnett International.
Philadelphia, Pennsylvania. November 19, 2003.
Forging sustained successes in CE: Fundamentals of the business plan. ACPE 10 th Invitational
Conference on Continuing Pharmaceutical Education. Seattle, Washington. September 19, 2003.
Challenging practice standards in chemotherapy-induced nausea and vomiting: Bridging the treatment
spectrum. Association of Community Cancer Centers Annual Meeting. Washington, DC. March 7,
2005.
CONTINUING EDUCATION PROGRAMS
Microcomputer basics for pharmacy personnel. Pennsylvania Society of Hospital Pharmacists Midyear
Clinical Meeting. Pittsburgh, Pennsylvania. 1987.
Steroid pharmacodynamics. Pennsylvania Outreach Program, Warren State Hospital. Warren,
Pennsylvania. 1987.
A perspective on glucocorticoids. Pennsylvania Outreach Program, Woodville State Hospital.
Pittsburgh, Pennsylvania. 1987.
Glucocorticoid basics. Value Drug Company Annual Stockholders' Meeting. Altoona, Pennsylvania.
1988.
Thromboembolic Disorders. Second Annual Spring Seminar, University of Pittsburgh at Johnstown.
Johnstown, Pennsylvania; 29th Annual University of Pittsburgh Continuing Education Spring Seminar.
Pittsburgh, Pennsylvania. 1988.
Myocardial reperfusion: Selection of a thrombolytic. Eighth Annual Aging Conference, University of
Pittsburgh at Johnstown. Johnstown, Pennsylvania. 1988.

Gordon J. Vanscoy
Page 28
Low intensity anticoagulation. Anticoagulant Therapy: Current Concepts and Controversies. Pittsburgh,
Pennsylvania. 1988.
Evolving therapeutic strategies in acute myocardial infarction. University of Pittsburgh Thrombolysis
Conference. Pittsburgh, Pennsylvania. 1988.
Contrasting non-steroidal drugs: Is there an agent of choice? Value Drug Company Annual Stockholders
Meeting. Altoona, Pennsylvania. 1989.
Clinical applications of non-steroidal drugs. 30th Annual Spring Continuing Education Seminar,
University of Pittsburgh School of Pharmacy. Pittsburgh, Pennsylvania. 1989.
Preventing non-steroidal drug adverse effects. Pennsylvania Pharmaceutical Association Annual
Meeting. Wilkes-Barre, Pennsylvania. 1989.
Evolving therapeutic strategies in acute myocardial infarction. Second Annual University of Pittsburgh
Thrombolysis Conference. Pittsburgh, Pennsylvania. 1989.
Anticoagulation: Controversy in U.S. vs. U.K. standards. Lackawanna County Pharmaceutical Society.
Scranton, Pennsylvania. 1989.
Evolving therapeutic strategies in acute myocardial infarction. University of Pittsburgh Outreach
Program. Indiana, Pennsylvania; Butler County Hospital Pharmacists Program. Butler, Pennsylvania;
University of Pittsburgh Outreach Program. Indiana, Pennsylvania. 1990.
Cardiovascular pharmacogeriatrics. Thirtieth Annual University of Pittsburgh Continuing Education
Spring Seminar. Pittsburgh, Pennsylvania. 1990.
Pharmacy-based anticoagulation services. Pennsylvania Society of Hospital Pharmacists Midwinter
Conference XI. Champion, Pennsylvania. 1990.
Drug information and pharmacoepidemiology. Medical Toxicology Grand Rounds, Montefiore
University Hospital. Pittsburgh, Pennsylvania. 1990.
Evolving therapeutic strategies in acute myocardial infarction. Pennsylvania Pharmaceutical Association
House of Delegates Meeting. Harrisburg, Pennsylvania; West Virginia Society of Hospital Pharmacist
Midyear Clinical Meeting. Charleston, West Virginia; Northeastern Chapter of the Pennsylvania Society
of Hospital Pharmacist Meeting. Wilkes-Barre, Pennsylvania; Northcentral Chapter of the Pennsylvania
Society of Hospital Pharmacist Meeting. Williamsport, Pennsylvania; Barbour, Randolph, Tucker and
Upsher Co. Pharmacists Association Meeting. Elkins, West Virginia; Mon Valley Pharmacists Meeting,
Monongahela Valley Hospital. Charleroi, Pennsylvania; Howard Co. Society of Hospital Pharmacists
Monthly Meeting, Baltimore, Maryland; Fayette Co. Pharmaceutical Association Monthly Meeting.
Uniontown, Pennsylvania; The George Washington University Medical Center Pharmacists Meeting.
Bethesda, Maryland. 1991.
Update on antithrombotics. Value Drug Company Annual Stockholders Meeting. Altoona,
Pennsylvania. 1991.

Gordon J. Vanscoy
Page 29
Polypharmacy and the elderly: Just say no! University of Pittsburgh Offices of Education and Regional
Programming Telecommunication Conference. Pittsburgh, Pennsylvania. 1992.
Emboli, infarcts and accidents. Fourth Annual University of Pittsburgh Thrombolysis Conference.
Pittsburgh, Pennsylvania. 1992.
Evolving therapeutic strategies in acute myocardial infarction. Rutgers University Continuing Education
Program. Newark, New Jersey; Sixth Annual Spring Seminar. Cambria-Somerset Council for
Continuing Education of Health Professionals, University of Pittsburgh at Johnstown. Johnstown,
Pennsylvania; PSHP and WVSHP Twenty-fourth Annual Assembly. Champion, Pennsylvania; VSHP
Meeting. Richmond Virginia; Indiana Society of Hospital Pharmacists Meeting. Fort Wayne, Indiana.
1992.
Evolving therapeutic strategies in acute myocardial infarction. Central Pennsylvania Pharmacy Director
Forum. State College, Pennsylvania, January 26, 1993; Central Michigan Pharmacist Association.
Lansing, Michigan, March 4, 1993; Indiana Pharmacy Group Meeting. Fort Wayne, Indiana, May 16,
1993; Houston Pharmacy Directors Group Meeting. Houston, Texas, April 15, 1993; Saginaw Pharmacy
Consortium Meeting. Saginaw, Michigan, May 4, 1993; Northern Indiana Society of Hospital
Pharmacists Meeting. South Bend, Indiana, May 11, 1993.
Clinical and economic considerations of AMI management post-GUSTO. Ohio Pharmacy Administrators
Group. September 27, 1993.
Evolving therapeutic strategies in acute myocardial infarction. Northcentral Chapter of the Pennsylvania
Society of Hospital Pharmacist Meeting. Williamsport, Pennsylvania, September 14, 1993; Central
Pennsylvania Pharmacy Director's Forum. State College, Pennsylvania, January 25, 1994; Eastern
Chapter of the Maryland Society of Hospital Pharmacists Meeting. Ocean City, Maryland, April 7, 1994;
6 th Annual Pittsburgh Thrombolysis Conference. Pittsburgh, Pennsylvania, April 26, 1994; Wilmington
Chapter of the Delaware Society of Hospital Pharmacists Meeting. Wilmington, Delaware, May 5, 1994;
American Society of Health-System Pharmacy State Chapter Officers Invitational Meeting. Miami,
Florida. December 4, 1994.
Evolving therapeutic strategies in acute myocardial infarction: A critical pathway approach. Northwestern
Pennsylvania Society of Hospital Pharmacists Meeting. Wilkes Barre, Pennsylvania. April 11, 1995;
Annual Meeting. Pennsylvania Society of Health-System Pharmacists. Champion, Pennsylvania.
October 19, 1995; Delaware Society of Health-System Pharmacists Annual Meeting. Dover, Delaware.
November 11, 1995; ASHP Midyear Clinical Meeting Exhibitors Theatre. Las Vegas, Nevada.
December 5, 1995.
Critical pathways: Pharmacotherapy of myocardial infarction. Quality Improvement in Acute Myocardial
Infarction: Today’s Pathways to Tomorrow’s Progress. ASHP Annual (Pre-meeting) Symposia.
Philadelphia, Pennsylvania, June 4, 1995; ASHP Annual (pre-meeting symposia) Midyear Clinical
Meeting. Las Vegas, Nevada. December 3, 1995.
New frontiers in anticoagulant and antiplatelet therapy. Northwest Chapter of Hospital Pharmacists
Meeting. Erie, Pennsylvania. April 28, 1995; American Society of Health-System Pharmacists Annual
Meeting Exhibitors Theatre. Philadelphia, Pennsylvania. June 5, 1995; Florida Society of Health-System
Pharmacists. Orlando, Florida. August 5, 1995; California Society of Health-System Pharmacists Annual
Meeting. Palm Springs, California. October 28, 1995; ASHP Midyear Clinical Meeting Exhibitors
Theatre. Las Vegas, Nevada. December 4, 1995.

Gordon J. Vanscoy
Page 30
Contemporary use of oral anticoagulation. Westmoreland Society of Health-System Pharmacists.
Greensburg, Pennsylvania. September 21, 1995.
Oral anticoagulation: Improving the risk-benefit ratio. University of Pittsburgh Alumni Weekend.
Hidden Valley Mountain Resort. Donegal, Pennsylvania. May 20, 1996.
Evolving therapeutic strategies in acute myocardial infarction: A critical pathway approach. Northcentral
Ohio Society of Health-System Pharmacists. Port Clinton, Ohio. February 13, 1996; University of
Pittsburgh Thrombolysis Conference. Pittsburgh, Pennsylvania. March 5, 1996; APhA Annual Meeting.
Nashville, Tennessee. March 12, 1996; University of Pittsburgh Thrombolysis Satellite Conference.
Cleveland, Ohio. May 22, 1996.
New frontiers in anticoagulation and antiplatelet therapy. Southern Gulf Society of Hospital Pharmacists.
Ft. Myers, Florida. February 19, 1996; American College of Clinical Pharmacy Annual Meeting.
Nashville, Tennessee. August 6, 1996; Pittsburgh, Pennsylvania, September 10, 1996; Washington, DC,
November 21, 1996; ASHP Midyear Clinical Meeting Exhibitors Theater. New Orleans, Louisiana.
December 9, 1996.
Critical pathways to impacting outcomes: Pharmacotherapy of AMI. Central Pennsylvania Society of
Health-System Pharmacists. Altoona, Pennsylvania. June 17, 1996; Implications for Disease State
Management. Washington, DC. September 28, 1996; ASHP Annual Midyear Clinical Meeting
Exhibitors Theatre. New Orleans, Louisiana. December 10, 1996.
Contemporary use of oral anticoagulation. Pennsylvania Society of Consultant Pharmacists. Allentown,
Pennsylvania. September 12, 1996.
Therapeutic frontiers in acute ischemic stroke. Delaware Society of Health-System Pharmacists. Lewes,
Delaware. September 14, 1996; University of Pittsburgh Fall CE Seminar. Pittsburgh, Pennsylvania.
November 17, 1996; ASHP Annual Midyear Clinical Meeting (pre-meeting symposia). New Orleans,
Louisiana. December 9 and December 10, 1996.
National smoking cessation specialist certification program. Thrift Drug Company. Pittsburgh,
Pennsylvania. December 5, 1996.
HIV/AIDS pharmacist certification program. University of Pittsburgh Spring CE Program. Pittsburgh,
Pennsylvania. April 5 and April 12, 1997.
National smoking cessation specialist certification program. Publix Supermarket Pharmacy. Atlanta,
Georgia. February 20, 1997; Kroger. April 16, 1997; University of Pittsburgh Alumni Weekend. Hidden
Valley Resort. Donegal, Pennsylvania. May 18, 1997; United States Navy. Pittsburgh, Pennsylvania.
June 30, 1997.
Therapeutic frontiers in acute ischemic stroke. Northwestern Ohio Society of Health-System
Pharmacists. Sandusky, Ohio. April 28, 1997.
New frontiers in antiplatelet and anticoagulant therapy. Pittsburgh, Pennsylvania. February 20, 1997;
Maryland Society of Health-System Pharmacists. Baltimore, Maryland. March 13, 1997; Texas Society
of Health-System Pharmacists Annual Meeting. Austin, Texas. April 14, 1997; ASHP Annual Meeting

Gordon J. Vanscoy
Page 31
Exhibitors Theater. Minneapolis, Minnesota. June 2, 1997; St. Vincent’s Hospital. Jacksonville, Florida.
June 12, 1997; Tallahassee Chapter of the Florida Society of Health-System Pharmacists. Tallahassee,
Florida. June 12, 1997; Philadelphia, Pennsylvania. June 19, 1997; Boston Massachusetts. October 21,
1997; Academy of Managed Care Pharmacy Educational Conference. Seattle, Washington. November 2,
1997; Colorado Society of Health-System Pharmacists. Denver, Colorado. November 12, 1997;
American Society of Health-System Pharmacists Midyear Clinical Meeting. Atlanta, Georgia. December
8, 1997.
Critical pathways to improving outcomes: Pharmacotherapy of acute myocardial infarction.
Conshohcken, Pennsylvania. September 16, 1997; Detroit, Michigan. October 7, 1997; American
Society of Health-System Pharmacists Midyear Clinical Meeting. Atlanta, Georgia. December 7, 1997;
Manchester, New Hampshire. December 10, 1997; Rochester, New York. December 1997.
Ischemic brain attack: Medication pathways to reducing disability. Washington, D.C. March 25, 1998;
New Hampshire Society of Health-System Pharmacists. Manchester, New Hampshire. May 6, 1998;
Houston, Texas. August 6, 1998; Georgia Society of Health-System Pharmacists Meeting. Atlanta,
Georgia. September 17, 1998; Maryland Society of Health-System Pharmacists Meeting. Baltimore,
Maryland. October 1, 1998; California Society of Health-System Pharmacists Annual Meeting.
Anaheim, California. October 23, 1998; American Society of Health-System Pharmacists Midyear
Clinical Meeting. Las Vegas, Nevada. December 7, 1998.
AMI pathway: Shifting the formulary paradigm. Pittsburgh, Pennsylvania. March 10, 1998;
Washington, D.C. March 25, 1998; Scranton, Pennsylvania. May 12, 1998; American Society of Health-
System Pharmacists Annual Meeting. Baltimore, Maryland. June 2, 1998; Houston, Texas. August 6,
1998; Georgia Society of Health-System Pharmacists Meeting. Atlanta, Georgia. September 17, 1998;
Maryland Society of Health-System Pharmacists Meeting. Baltimore, Maryland. October 1, 1998;
Rochester, New York. October 21, 1998; California Society of Health-System Pharmacists Annual
Meeting. Anaheim, California. October 23, 1998; American Society of Health-System Pharmacists
Midyear Clinical Meeting. Las Vegas, Nevada. December 7, 1998.
Acute coronary syndromes: Emerging preeminence of antiplatelet therapy. Pittsburgh, Pennsylvania.
January 15, 1998; Dallas, Texas. February 10, 1998; Hershey, Pennsylvania. May 19, 1998; American
Society of Health-System Pharmacists Annual Meeting. Baltimore, Maryland. June 1, 1998; Columbus,
Ohio. June 9, 1998; Florida Society of Health-System Pharmacists Annual Meeting. Orlando, Florida.
August 8, 1998; New York City Society of Health-System Pharmacists Meeting. New York, New York.
September 9, 1998; Indianapolis, Indiana. September 23, 1998; California Society of Health-System
Pharmacists Annual Meeting. Anaheim, California. October 23, 1998; American Society of Health-
System Pharmacists Midyear Clinical Meeting. Las Vegas, Nevada. December 7, 1998.
Clinical perspectives in antithrombotic therapy. Pennsylvania Pharmacists Association 1998 Annual
Meeting. Mars, Pennsylvania. July 16, 1998.
Establishing coordinated anticoagulation services. Bux-Mont Chapter of the Pennsylvania Society of
Health-System Pharmacists Meeting. Philadelphia, Pennsylvania. March 9, 1999.
Myocardial infarction: An evidence-based approach to pharmacotherapy. University of Pittsburgh
Millenium Series. Pittsburgh, Pennsylvania. May 6, 1999; Montpelier, Vermont. November 1, 1999;
Rochester, New York. December 6, 1999; Orlando, Florida. December 6, 1999.

Gordon J. Vanscoy
Page 32
Acute coronary syndromes: Preeminence of antiplatelet therapy. American College of Clinical
Pharmacy/ International College of Clinical Pharmacology Annual Meeting. Orlando, Florida. April 13,
1999; New York City Society of Health-System Pharmacists Meeting. New York, New York. May 11,
1999; American Society of Health-System Pharmacists Annual Meeting. Reno, Nevada. June 6, 1999;
Amerinet/Vector National Meeting. Orlando, Florida. June 24, 1999; Virginia and District of Columbia
Societies of Health-System Pharmacists Joint Meeting. Washington, D.C. June 29, 1999.
Brain attack: Pursuing enhanced outcomes. Southeastern Chapter of the Pennsylvania Society of Health-
System Pharmacists Meeting. Harrisburg, Pennsylvania. April 7, 1999; University of Pittsburgh
Millenium Series. Pittsburgh, Pennsylvania. May 6, 1999; American Society of Health-System
Pharmacists Annual Meeting. Reno, Nevada. June 5, 1999; North-Central Chapter of the Pennsylvania
Society of Health-System Pharmacists Meeting. Wilkes-Barre, Pennsylvania. June 15, 1999; Montpelier,
Vermont. November 11, 1999.
Thrombolytics in the new millenium. Indiana College of Clinical Pharmacy. Fort Harrison, Indiana.
November 18, 1999.
Managing the urokinase shortage: clinical and economic alternatives in peripheral arterial occlusion and
catheter clearance. American Society of Health Systems Pharmacists Midyear Clinical Meeting.
Orlando, Florida. December 6, 1999.
Opportunities for enhancing economic value: Improving management of venous thrombosis through an
outpatient approach. Texas Association Health Plans Annual Meeting. Houston, Texas. May 11, 2000.
Optimizing the acute coronary syndrome formulary: Balancing cost and quality. American Society of
Health System Pharmacists Midyear Clinical Meeting. Las Vegas, Nevada. December 4, 2000.
State-of-the-art antiplatelet therapies in ACS: A global perspective. Integrating evidence into practice.
Las Vegas, Nevada. December 1, 2000.
Managing peripheral arterial occlusion and central venous catheter clearance with fibrinolytics: clinical
and economic alternatives. Richmond, Virginia. June 1, 2000; Melville, New York. March 27, 2001.
Acute coronary syndromes: Preeminence of antiplatelet therapy. American Society of Health System
Pharmacists Annual Meeting. Philadelphia, Pennsylvania. June 4, 2000; South Bend, Indiana. July 8,
2000; American Society of Health System Pharmacists Midyear Clinical Meeting. December 4, 2001.
Arterial fibrinolysis: Targeting myocardial infarction and stroke. McClean, Virginia. April 13, 2000;
Pittsburgh, Pennsylvania. May 5, 2000; Scranton, Pennsylvania. May 22, 2000; Richmond, Virginia.
June 1, 2000; Baltimore, Maryland. June 22, 2000; Lexington, Kentucky. July 11, 2000; Harrisburg,
Pennsylvania. September 13, 2000; Catholic Healthcare West Care Management Clinical Pharmacy
Council Meeting. San Francisco, California. September 29, 2000. Melville, New York. March 27,
2001; Greater Washington Area Society of Healthsystem Pharmacists Meeting. McClean, Virginia.
February 21, 2001.
Defusing thrombotic risk with an evidence-based LMWH formulary. Johnson City, Tennessee. March
23, 2000. Chicago, Illinois. April 12, 2000; Nashville, Tennessee. April 18, 2000; Pittsburgh,
Pennsylvania. May 4, 2000; Durham, North Carolina. May 16, 2000; Washington, DC. May 17, 2000;
American Society of Health System Pharmacists Annual Meeting. June 4, 2000; Tampa, Florida. June

Gordon J. Vanscoy
Page 33
13, 2000; Charleston, South Carolina. August 1, 2000; McClean, Virginia. August 8, 2000; Erie,
Pennsylvania. August 24, 2000; St. Louis, Missouri. September 26, 2000; American Society of Health
System Pharmacists Midyear Clinical Meeting. Las Vegas, Nevada. December 3, 2000; Amherst, New
York. January 24, 2001.
Integrating new fibrinolytic findings into AMI reperfusion and combination therapy. New York
Academy of Medicine. New York City, New York. May 9, 2001; Delaware Valley Chapter of the
Pennsylvania Society of Health-System Pharmacists Meeting. Wilmington. Delaware.
October 15, 2001; American Society of Health-System Pharmacists Midyear Clinical Meeting. December
4, 2001. New Orleans, Louisiana.
Fibrinolysis of peripheral arterial and catheter thrombosis. Virginia Society of Health-System
Pharmacists Fall Seminar. Norfolk, Virginia. September 22, 2001; American Society of Health-System
Pharmacists Midyear Clinical Meeting. December 4, 2001. New Orleans, Louisiana.
Consensus on LMWH differentiation: Issues and evolving evidence. Philadelphia, Pennsylvania. April
10, 2001; State College, Pennsylvania. May 2, 2001; Monroeville, Pennsylvania. May 23, 2001;
Pittsburgh, Pennsylvania. May 31, 2001; Erie, Pennsylvania. June 21, 2001; Melbourne, Florida. June
28, 2001; Detroit, Michigan. August 29, 2001; Southfield, Michigan. October 18, 2001; New
Brunswick, New Jersey. November 27, 2001.
Innovation in sepsis management: Managing value. Boca Raton, Florida. March 24, 2001; American
College of Clinical Pharmacy Spring Meeting. Salt Lake City, Utah. April 22, 2001; Beverly Hills,
California. June 15, 2001.
Scientific basis for therapeutic interchange: Results of the 2000 national consensus panel. Pennsylvania
Society of Health System Pharmacists Midyear Meeting XXII. March 16, 2001; Sacramento Valley
Society of Health System Pharmacists. Sacramento, California. June 5, 2001; Seattle, Washington.
June 7, 2001; California Society of Health-System Pharmacists Annual Meeting. Santa Clara, California.
October 26, 2001. American Society of Health-System Pharmacists Midyear Clinical Meeting. December
4, 2001. New Orleans, Louisiana.
Interrupting the sepsis cascade: Innovation in biotechnology. Baltimore, Maryland. June 19, 2001;
Chesapeake Society of Health System Pharmacist. Norfolk, Virginia. September 6, 2001; American
Society of Health-System Pharmacists Midyear Clinical Meeting. December 3, 2001. New Orleans,
Louisiana.
Are IIb's me too’s? Differentiating evidence and value. American Society of Health-System Pharmacists
Midyear Clinical Meeting. December 3, 2001. New Orleans, Louisiana.
Consensus on LMWH differentiation: Issues and evolving evidence. The Cleveland Clinic. February 5,
2002. Cleveland, Ohio.
Integrating new fibrinolytic findings into AMI reperfusion and combination therapy: 2002 and beyond.
Delaware Valley Chapter of the Pennsylvania Society of Health-System Pharmacists Meeting. March 7,
2002. Wilmington, Delaware; March 26, 2002. Ft. Lauderdale, Florida; April 4, 2002. Pittsburgh,
Pennsylvania; April 23, 2002. Savannah, Georgia; June 27, 2002. Dallas, Texas; Georgia Society of
Health-System Pharmacists Summer Meeting. July 13, 2002. Amelia Island, Florida; August 14, 2002.
Louisville, Kentucky.

Gordon J. Vanscoy
Page 34
Fibrinolysis of catheter and peripheral arterial thrombosis. April 4, 2002. Pittsburgh, Pennsylvania; June
27, 2002. Dallas, Texas; November 21, 2002. Brooklyn, New York.
Therapeutic interchange: Application to LMWHs? April 25, 2002. Quincy, Massachusetts; September
19, 2002. Baltimore, Maryland; October 15, 2002. Kansas City, Missouri.
Maximizing the value of Sepsis Management with Drotrecogin Alfa (activated). American College of
Clinical Pharmacy Annual Meeting Exhibitor Classroom. October 20, 2002. Phoenix, Arizona.
LMWH horizons: New uses, new evidence, new agents. American Society of Health-System Pharmacists
Annual Meeting. June 10, 2002. Baltimore, Maryland; June 10, 2002. Indianapolis, Indiana; June 26,
2002. Houston, Texas; August 26, 2002. Clifton Springs, New York; October 25, 2002. Mountain
Brook (Birmingham), Alabama; American Society of Health-System Pharmacists Midyear Clinical
Meeting. December 10, 2002. Atlanta, Georgia.
Fibrinolysis horizons: 2003 and beyond. American Society of Health-System Pharmacists Midyear
Clinical Meeting. December 9, 2002. Atlanta, Georgia.
Integrating evolving evidence into sepsis management: Maximizing value with drotrecogin alfa
(activated). American Society of Health-System Pharmacists Midyear Clinical Meeting. December 9,
2002. Atlanta, Georgia.
Maximizing outcomes in anemia management: Focus on oncology. MedAssets. December 8, 2002.
Atlanta Georgia; American Society of Health-System Pharmacists Midyear Clinical Meeting. December
10, 2002. Atlanta, Georgia.
Maximizing outcomes in anemia management: Focus on oncology. February 12, 2003. Philadelphia,
Pennsylvania: February 25, 2003. Bethesda, Maryland; March 13, 2003. Philadelphia, Pennsylvania;
March 25, 2003. Pittsburgh, Pennsylvania; March 27, 2003. Chicago, Illinois; May 27, 2003. Consorta
Audio broadcast.
Challenging VTE standards: Heparin, LMWHs, and evolving agents. February 19, 2003. Greensburg,
Pennsylvania; April 29, 2003. Winston Salem, North Carolina; May 8, 2003. Fort Lauderdale, Florida.
September 4, 2003. Baltimore, Maryland. October 15, 2003. Hickory, North Carolina.
LMWHs in cardiology: 2003 and beyond. March 6, 2003. Monroeville, Pennsylvania; September 23,
2003. Niles, Ohio.
Optimizing injectable anticoagulant formulary management: Considerations with LMWH interchange
and novel agents. March 19, 2003. Wilkes-Barre, Pennsylvania; April 2, 2003. Rochester, New York;
April 9, 2003. Mountainside, New Jersey; June 3, 2003. Raleigh, North Carolina.
Making informed formulary decisions: Focus of fibrinolytics. April 15, 2003. Pittsburgh, Pennsylvania;
Novation audio conference. July 22, 2003; Med Assets audio conference. July 24, 2003, August 19,
2003, August 26, 2003; PACT audio conference. August 20, 2003. Broadlane audio conference. June
12, 2003, September 3, 2003; Broadlane audio conference. June 12, 2003. Novation audio conference;
December 8, 2003. American Society of Health-System Pharmacists Midyear Clinical Meeting. New
Orleans, Louisiana.

Gordon J. Vanscoy
Page 35
Evolving practices in oncology-associated anemia: Bringing experience and emerging data into focus.
October 18, 2003. Manalapan, Florida.
Challenging practice standards in oncology-associated anemia: In pursuit of synchronized treatment.
October 22, 2003. Long Island, New York; November 2, 2003. Atlanta, Georgia; November 5, 2003.
Durham, North Carolina; December 3, 2003. Los Angeles, California; December 10, 2003. Sacramento,
California; December 18, 2003. New York, New York.
Emerging data and economics of drotrecogin in severe sepsis. November 3, 2003. Atlanta, Georgia;
November 19, 2003. Philadelphia, Pennsylvania; December 8, 2003. New Orleans, Louisiana; December
9, 2003. New Orleans, Louisiana.
Oncology-associated anemia: Optimizing the value of erythropoietic growth factors. December 8, 2003.
New Orleans, Louisiana.
Challenging practice standards in oncology-associated anemia: In pursuit of synchronized treatment.
January 7, 2004. Audio broadcast, New York, New York;. January 8, 2004. East Meadow, New York;
March 9, 2004. Piscataway, New Jersey; March 10, 2004. Pompton Plains, New Jersey; March 18, 2004.
Birmingham, Alabama; March 25, 2004. Newington, Connecticut; April 29, 2004. West Hartford,
Connecticut; May 26, 2004. Springfield, Massachusetts; May 27, 2004. Burlington, Massachusetts; May
27, 2004. Needham, Massachusetts; June 10, 2004. West Orange, New Jersey.
Cancer support innovation: Pharmacy and therapeutic considerations in chemotherapy-induced
neutropenia and anemia symposium. American Society of Health-System Pharmacists Annual Meeting.
June 21, 2004. Las Vegas, Nevada.
Late-breaking evidence: Inpatient darbepoetin: Conversions, costs, and critical use. American Society of
Health-System Pharmacists Annual Meeting. June 22, 2004. Las Vegas, Nevada.
Concisely evaluating a formulary class across indications: 2004 fibrinolytic model. October 26, 2004.
Baltimore, Maryland; November 9, 2004. Pittsburgh, Pennsylvania; March 17, 2005. Bridgewater, New
Jersey.
Cancer support innovation: Pharmacy and therapeutic considerations in chemotherapy induced
neutropenia and anemia. October 24, 2004. Dallas, Texas; California Society of Health-System
Pharmacists Annual Meeting. November 5, 2004. Long Beach, California.
Challenging the heparin paradigm in VTE: The evidence-based role of LMWHs. California Society of
Health-System Pharmacists Annual Meeting. November 5, 2004. Long Beach, California; March 17,
2005. Bridgewater, New Jersey.
Consensus on contemporary UFH issues: Medication errors with heparins. American Society of Health-
System Pharmacists Midyear Clinical Meeting. December 5, 2004. Orlando, Florida.
Challenging practice standards in chemotherapy induced nausea and vomiting: Bridging the treatment
spectrum. American Society of Health-System Pharmacists Midyear Clinical Meeting. December 7,
2004. Orlando, Florida.
EDUCATIONAL PROGRAMS

Gordon J. Vanscoy
Page 36
Pharmacogeriatrics. Gerontology: A multi-disciplinary approach to practice. Aspinwall Veterans Affairs
Hospital. Pittsburgh, Pennsylvania. 1986.
Advances in angiotensin converting enzyme inhibitors. Primary Care Clinical Rounds, Veterans Affairs
Hospital. Pittsburgh, Pennsylvania. 1986.
New anti-arrhythmics. Primary Care Clinical Rounds, Veterans Affairs Hospital. Pittsburgh,
Pennsylvania. 1987.
Update on drug information retrieval systems. Medical Continuing Education Conference, Veterans
Affairs Hospital. Pittsburgh, Pennsylvania. 1988.
Drugs and the elderly. Gerontology: A multi-disciplinary approach to practice. Aspinwall Veterans
Affairs Hospital. Pittsburgh, Pennsylvania. 1987.
Low intensity oral anticoagulation. Pharmacology Update on Select Classification of Drugs. Veterans
Affairs Hospital. Aspinwall, Pennsylvania. 1988.
Anticoagulation clinics. Faculty Education Program. University of Pittsburgh School of Pharmacy.
Pittsburgh, Pennsylvania. 1988.
Thrombolytic update. Veterans Affairs Hospital, Department of Pharmacy. Pittsburgh, Pennsylvania.
1989.
Pharmacy applications of DBase III Plus in monitoring antibiotic usage. Veterans Affairs Hospital,
Department of Pharmacy. Pittsburgh, Pennsylvania. 1989.
Review of narcotic pharmacology. Veterans Affairs Hospital, Pain Consult Service. Pittsburgh,
Pennsylvania. 1989.
Drug information for critical care satellites. Presbyterian University Hospital, Department of Pharmacy.
Pittsburgh, Pennsylvania. 1989.
Update on anti-ulcer therapies. Veterans Affairs Hospital, Department of Pharmacy. Pittsburgh,
Pennsylvania. 1989.
Controversy in monitoring oral anticoagulant therapy. Medical Resident Rounds, Veterans Affairs
Hospital. Pittsburgh, Pennsylvania. 1990.
Introduction to drug information services. Presbyterian University Hospital, Department of Pharmacy.
Pittsburgh, Pennsylvania. 1990.
Hospital pharmacy career roundtable discussion on drug information. Pennsylvania Society of Hospital
Pharmacists Midyear Meeting. Pittsburgh, Pennsylvania. 1991.
ETSAMI program faculty retreat. University of Pittsburgh School of Pharmacy. Pittsburgh,
Pennsylvania. 1992.

Gordon J. Vanscoy
Page 37
Report on innovative ambulatory practice. University of Pittsburgh School of Pharmacy Board of
Visitors. Pittsburgh, Pennsylvania. October 21, 1992.
Hospital pharmacy career roundtable discussion on drug information. Pennsylvania Society of Hospital
Pharmacists Midyear Meeting. Pittsburgh, Pennsylvania. October 22, 1992.
ETSAMI adjunct program faculty update. University of Pittsburgh School of Pharmacy Educational
Program. Orlando, Florida. December 5, 1992.
Report on the design and implementation of the UPMC Drug Advisory Program. University of
Pittsburgh School of Pharmacy Board of Visitors. Pittsburgh, Pennsylvania. October 28, 1993.
Career roundtables: ambulatory care. Western Chapter of the Pennsylvania Society of Hospital
Pharmacists Meeting. Pittsburgh, Pennsylvania. October 28, 1993.
University of Pittsburgh ETSAMI program faculty update. Atlanta, Georgia. December 5, 1993.
Specialty practice group in drug information business session. Twenty-eighth Annual ASHP Midyear
Clinical Meeting. Atlanta, Georgia. December 6, 1993.
University of Pittsburgh ETSAMI program faculty retreat. New Orleans, Louisiana. January 21, 1994
through January 23, 1994.
Optimizing patient management: The role of organized anticoagulation services. Allegheny
Clinical Optimization of Antithrombotics Group. Pittsburgh, Pennsylvania. March 2, 1994.
National drug information strategic planning retreat. Consortium for the Advancement of Medication
Information, Policy and Research. Hilton Head, South Carolina. June 3, 1994 through June 5, 1994.
Career roundtables: Ambulatory care. Western Chapter of the Pennsylvania Society of Hospital
Pharmacists Meeting. Pittsburgh, Pennsylvania. October 27, 1994.
University of Pittsburgh ETSAMI program faculty update. Miami, Florida. December 4, 1994.
CAMIPR next step update. Miami, Florida. December 6, 1994.
Drug information. University of Pittsburgh Wellness Fair. Pittsburgh, Pennsylvania. March 20, 1995.
University of Pittsburgh ETSAMI program faculty retreat. Ft. Lauderdale, Florida. April 21, 1995
through April 23, 1995.
Melatonin - myth or miracle? Blue Cross of Western Pennsylvania HealthPlace. Pittsburgh,
Pennsylvania. November 27, 1995.
New frontiers in anticoagulation and antiplatelet therapy. University Pharmacotherapy Associates
Faculty Update. Las Vegas, Nevada. December 3, 1995.
Evolving therapeutic strategies in acute myocardial infarction. University of Pittsburgh Program Faculty
Update. Las Vegas, Nevada. December 4, 1995.

Gordon J. Vanscoy
Page 38
Consortium for the Advancement of Medication Information Policy and Research planning meeting. Las
Vegas, Nevada. December 5, 1995.
University of Pittsburgh national cardio/cerebrovascular pharmacotherapeutics programs faculty update
meeting. New Orleans, Louisiana. December 8, 1996.
New frontiers in antiplatelet and anticoagulant therapy. University Pharmacotherapy Associates Faculty
Update Meeting. New Orleans, Louisiana. December 8, 1996.
Consortium for the Advancement of Medication Information, Policy and Research planning meeting.
New Orleans, Louisiana. December 8, 1996.
University of Pittsburgh national cardio/cerebrovascular pharmacotherapeutics programs faculty retreat.
Naples, Florida. April 18, 1997 through April 20, 1997.
New frontiers in antiplatelet and anticoagulant therapy. University Pharmacotherapy Associates faculty
retreat. Palm Beach, Florida. May 23, 1997 through May 25, 1997.
University of Pittsburgh national cardio/cerebrovascular pharmacotherapeutics programs faculty update
meeting. New Orleans, Louisiana. December 7, 1997.
New frontiers in antiplatelet and anticoagulant therapy. University Pharmacotherapy Associates Faculty
Update Meeting. New Orleans, Louisiana. December 8, 1997.
University of Pittsburgh national smoking cessation certification program advisory retreat. Key Largo,
Florida. February 6, 1998 through February 8, 1998.
University of Pittsburgh national cardio/cerebrovascular pharmacotherapeutics programs faculty retreat.
San Francisco, California. March 13, 1998 through March 15, 1998.
University Pharmacotherapy Associates acute coronary syndromes faculty retreat. Orlando, Florida.
April 16, 1998 through April 19, 1998.
University of Pittsburgh national cardio/cerebrovascular pharmacotherapeutics programs faculty update
meeting. Las Vegas, Nevada. December 6, 1998.
University Pharmacotherapy Associates, LLC, acute coronary syndromes national faculty retreat.
Farmington, Pennsylvania. January 29, 1999 through January 31, 1999.
University of Pittsburgh national cardio/cerebrovascular pharmacotherapeutics programs faculty retreat.
Ft. Lauderdale, Florida. May 14, 1999 through May 16, 1999.
University Pharmacotherapy Associates, LLC, thromboembolism national faculty retreat. Farmington,
Pennsylvania. January 28, 2000 through January 30, 2000.
University of Pittsburgh national cardio/cerebrovascular pharmacotherapeutics programs faculty retreat.
Orlando, Florida. February 25, 2000 through February 27, 2000.

Gordon J. Vanscoy
Page 39
University Pharmacotherapy Associates, LLC, acute coronary syndromes national faculty retreat.
Phoenix, Arizona. May 12, 2000 through May 14, 2000.
University Pharmacotherapy Associates, LLC, acute coronary syndrome and thromboembolism national
faculty retreat. Key Largo, Florida. January 26, 2001 through January 28, 2001.
University Pharmacotherapy Associates, LLC, sepsis national faculty retreat. Farmington, Pennsylvania.
February 23, 2001 through February 25, 2001.
University of Pittsburgh national fibrinolysis programs faculty retreat. Orlando, Florida. May 17, 2001
through May 20, 2001.
University Pharmacotherapy Associates, LLC, sepsis treatment guidelines and DUE criteria invitational
panel. Boca Raton, Florida. March 23, 2001 through March 25, 2001; Beverly Hills, California. June
14, 2001 through June 16, 2001.
University Pharmacotherapy Associates, LLC, therapeutic interchange of LMWHs scientific advisory
panel. New Orleans, Louisiana. November 16, 2001 through November 18, 2001.
University of Pittsburgh national cardio-thromboembology pharmacotherapeutics programs faculty
update meeting. New Orleans, Louisiana. December 2, 2001.
University Pharmacotherapy Associates, LLC, sepsis national faculty retreat. Cancun, Mexico. January
18, 2002 through January 21, 2002.
University of Pittsburgh national fibrinolysis programs faculty retreat. Farmington, Pennsylvania.
February 22, 2002 through February 23, 2002.
University Pharmacotherapy Associates, LLC, thromboembolism national faculty retreat. Farmington,
Pennsylvania. February 23, 2002 through February 24, 2002.
University Pharmacotherapy Associates, LLC, overcoming barriers to sepsis management invitational
panel. San Francisco, California. April 19, 2002 through April 21, 2002.
University Pharmacotherapy Associates, LLC, science and practice crossroads: redefining LMWH
guidelines and pathways. Bal Harbor, Florida. March 15, 2002 through March 17, 2002; Orlando,
Florida. May 17, 2002 through May 19, 2002; Martha’s Vineyard, Massachusetts. September 13, 2002
through September 15, 2002; Phoenix, Arizona. November 8, 2002 through November 10, 2002.
University Pharmacotherapy Associates, LLC, national anemia in oncology faculty retreat. Baltimore,
Maryland. June 1, 2002 through June 2, 2002.
University of Pittsburgh national cardio-thromboembology pharmacotherapeutics program faculty update
meeting. Atlanta, Georgia. December 8, 2002.
University Pharmacotherapy Associates, LLC, thromboembolism national faculty retreat. Nassau,
Bahamas. January 10, 2003 through January 12, 2003.

Gordon J. Vanscoy
Page 40
University of Pittsburgh national fibrinolysis faculty retreat. Pittsburgh, Pennsylvania. February 6, 2003
through February 7, 2003.
University Pharmacotherapy Associates, LLC, clarifying contemporary erythropoietic growth factor
issues: bringing science and practice into clear focus. San Francisco, California. February 14, 2003
through February 16, 2003.
University Pharmacotherapy Associates, LLC, challenging antithrombotic standards: has the time come
for change? San Francisco, California. March 7, 2003 through March 9, 2003; Cancun, Mexico. May
16, 2003 through May 18, 2003.
University Pharmacotherapy Associates, LLC, integrating recent science into sepsis management national
faculty retreat. Pittsburgh, Pennsylvania. March 21, 2003 through March 22, 2003.
University Pharmacotherapy Associates, LLC, challenging practice standards in oncology-associated
anemia: in pursuit of synchronized treatment. San Francisco, California. July 11, 2003 through July 13,
2003.
University Pharmacotherapy Associates, LLC, challenging practice standards in oncology-associated
anemia: bringing experience and emerging data into focus. West Palm Beach, Florida. October 17, 2003
through October 19, 2003.
University Pharmacotherapy Associates, LLC, pharmacy thought leader advisory board: erythropoietic
growth factors. New Orleans, Louisiana. December 6, 2003 through December 7, 2003.
University Pharmacotherapy Associates, LLC, national LMWH faculty retreat. Paradise Island,
Bahamas. January 16, 2004 through January 18, 2004.
University Pharmacotherapy Associates, LLC, national neutropenia faculty retreat. San Diego,
California. February 20, 2004 through February 22, 2004.
University Pharmacotherapy Associates, LLC, evidence and value crossroads: clarifying contemporary
erythropoietic growth factor issues. Orlando, Florida. March 12, 2004 through March 14, 2004.
University Pharmacotherapy Associates, LLC, national heart failure faculty retreat. Pittsburgh,
Pennsylvania. March 29, 2004.
University Pharmacotherapy Associates, LLC, challenging the effective use of heparin: consensus,
concerns and controversies. Sanibel, Florida. April 16, 2004 through April 18, 2004; Phoenix, Arizona.
ay 21, 2004 through May 23, 2004.
University Pharmacotherapy Associates, LLC, national anemia faculty retreat. Phoenix, Arizona. May
23, 2004, through May 24, 2004.
University Pharmacotherapy Associates, LLC, national chemotherapy-induced nausea and vomiting
faculty retreat. Pittsburgh, Pennsylvania. July 11, 2004 through July 12, 2004.
University Pharmacotherapy Associates, LLC, national anemia faculty retreat. Miami, Florida. January
21, 2005 through January 23, 2005.

Gordon J. Vanscoy
Page 41
University Pharmacotherapy Associates, LLC, national heart failure faculty retreat. San Francisco,
California. January 28 2005 through January 30, 2005.
University Pharmacotherapy Associates, LLC, national anemia in long term care faculty retreat.
Pittsburgh, Pennsylvania. March 20 2005 through March 21, 2005.
University Pharmacotherapy Associates, LLC, national LMWH faculty retreat. Pittsburgh, Pennsylvania.
May 22, 2005 through May 23, 2005.
RESEARCH INTERESTS
Systematic study of medication use in managed care populations with emphasis on economic outcomes.
Other areas of interest include oncology supportive care (anemia, neutropenia, CINV) and cardiothromboembology.
TEXTBOOK CHAPTERS
PUBLICATIONS
Vanscoy GJ. The Future of drug information: bracing for the cure. In: Malone P, Mosdell K, Kier, K,
Stanovich J, editors. Drug information: A guide for pharmacists. Norwalk: Appleton & Lange,
1996;389-405.
Vanscoy GJ, Castiglione B. Guidelines for anticoagulation provider certification: In: Ansell JE, Oertel
LB and Wittkowsky AK, editors. Managing Oral Anticoagulation Therapy: Clinical and operational
guidelines (suppl 1). Aspen Publishing Inc. Gaitherbsurg MD. 1998;3A-4:1-9.
Vanscoy GJ, Loken S. Guidelines for anticoagulation provider certification: In: Ansell JE, Oertel LB
and Wittkowsky AK, editors. Managing Oral Anticoagulation Therapy: Clinical and operational
guidelines. Aspen Publishing Inc. Gaitherbsurg MD. 2001; 3A-4: 1-12.
Vanscoy GJ, Loken S. Guidelines for anticoagulation provider certification: In: Ansell JE, Oertel LB
and Wittkowsky AK, editors. Managing Oral Anticoagulation Therapy: Clinical and operational
guidelines. Aspen Publishing Inc. Gaitherbsurg MD. 2003; 7:1-12.
Vanscoy GJ. Cost-effective drug selection: In: Clinical, Interventional and Investigational
Thrombocardiology. Becker RC, Harrington RA, Editors. Taylor & Francis, Publisher. Boca Raton, FL.
2005:167-169.
TEXTBOOK EDITOR
Vanscoy GJ, editor. Medication information and literature evaluation: Pharmacy 1400 coursebook.
Pittsburgh: University of Pittsburgh Press, 1996, 1995, 1994, 1993, 1992, 1991.

Gordon J. Vanscoy
Page 42
Vanscoy GJ, section editor. Cost-effective drug selection: Antiplatelets, anticoagulants, fibrinolytics. In:
Clinical, Interventional and Investigational Thrombocardiology. Becker RC, Harrington RA, Editors.
Taylor & Francis, Publisher. Boca Raton, FL. 2005.
PEER REVIEWED ARTICLES
Vanscoy GJ, Giudici RA, Mattei TJ. Development of a model for predicting pharmacy personnel
requirements. Hosp Pharm 1987;22(5):453-464.
Krokosky N, Vanscoy GJ. Running an anticoagulation clinic. Amer J Nursing 1989;89(10):1304-1306.
Vanscoy GJ, Giudici RA. Unit dose pharmacy workload forecasting: Validation of the pharmacy service
unit model. Hosp Pharm 1990;25(3):250-267.
Schneider S, Vanscoy G, Michelson E. Failure of cimetidine to affect phalloidin toxicity. Vet Hum
Toxicol 1991;33(1);17-19.
Vanscoy GJ, McAuley * J. Exaggerated warfarin response: A case report. Vet Hum Toxicol
1991;33(3);270-271.
Vanscoy GJ, Krause JR. Warfarin and the international normalized ratio: Reducing interlaboratory
effects. DICP Ann Pharmacother 1991;25(11):1190-1192.
Schlicht * JR, Stablein * AM, Vanscoy GJ. Confusing bacterial endocarditis recommendation. DICP Ann
Pharmacother 1991;25(12):1396-1397.
Vanscoy GJ, Krause JR. Comment: Warfarin and the international normalized ratio [letter]. DICP Ann
Pharmacother 1992;26(3):431.
Schlicht JR * , Stablein AM * , Vanscoy GJ. Comment: Confusing bacterial endocarditis recommendations
[letter]. DICP Ann Pharmacother 1992;26(5):716.
Schneider SM, Vanscoy GJ, Michelson E. Failure of n-acetylcysteine to reduce alpha-amanitin toxicity.
J Appl Toxicol 1992;12(2):141-2.
Shaughnessy AF, Schlicht JR * , Vanscoy GJ. Survey and evaluation of newsletters marketed to family
practice physicians. J Am Board Fam Pract 1992;5(4):573-9.
Schlicht * JR, Markind JE, Vanscoy GJ, Coccodrilli KR. Quinolone antibiotics. P&T 1993;18(3):280-9.
Vanscoy GJ. New therapeutic ranges for warfarin therapy. Hosp Pharm 1993;28(4):374-6.
Kendrach * MG, Vanscoy GJ. Current status of anti-retroviral agents and HIV. US Pharm 1993
Apr:H10-28.
Barron R, Vanscoy GJ. Natural products and the athlete: Facts and folklore. Ann Pharmacother
1993;27(4):607-15.
Vanscoy GJ, Coax W. Improving the risk-benefit ratio: Focus on the contemporary use of oral
anticoagulation. J Fam Pract 1995;31(3):261-69.

Gordon J. Vanscoy
Page 43
Gajewski LK, Vanscoy GJ, Dean JC, Bouzos CG. IRxBase: A computerized LAN-based investigational
drug information database. Hosp Pharm 1995;30(12):1113-18, 1120.
Mehta U, Vanscoy GJ. Improved anticoagulation: A protocol approach to heparin dosing. Hosp Pharm
1995;30(12):1161-64.
Vanscoy GJ, Gajewski LK, Gora-Harper ML, Grant KL, May RJ, Tyler LS. Drug information practice:
A CAMIPR consensus view. Ann Pharmacother 1996;30(7/8):876-81.
Vanscoy GJ. Linking the ivory tower and real-world practice: Building a synergy bridge in managed
care pharmacy. J Managed Care Pharmacy 1997;3(1):107-110.
Vanscoy GJ, Rock W. Credentialing of anticoagulation providers: A proposed model. J Thrombosis
and Thrombolysis 1998;5:S53-S61.
Vanscoy GJ. Outpatient management of venous thromboembolism. J Thrombosis and Thrombolysis
1999;7:109-112.
Gajewski LK, Grimone A, Melbourne K, Vanscoy GJ. Characterization of rash with indinavir in a
national patient cohort. Ann Pharmacother 1999;33:17-21.
Copley-Merriman K, Vanscoy GJ. Education and skills needed to conduct, interpret, and use economic
evaluations in healthcare. Value in Health 1999;2(2):88-91.
Vanscoy GJ, Rihn TL. GP IIb/IIIa receptor inhibitors: Clinical and cost considerations in acute coronary
syndromes. Formulary 1999;34(6):500-12.
Vanscoy GJ. The emergence of specialty pharmacy. JMCP 2000;6(4):208-215.
Merli GJ, Vanscoy GJ, Rihn TL, et al. Applying scientific criteria to therapeutic interchange: A balanced
analysis of low-molecular-weight heparins. J Thromb Thrombolysis 2001;11(3):247-259.
Rihn TL, Vanscoy GJ. Low-molecular weight heparins: Formulary drug class review. P&T
2001;26(9):486-494.
Vanscoy GJ. Management challenge with drotrecogin alfa (activated). Am J Health-Syst Pharm
2002;59:S19-S27.
Vanscoy GJ. Addendum: Innovations in sepsis management. Am J Health-Syst Pharm 2002;59:S28-
S29.
Vanscoy GJ, Rihn TL, Koerner PH. Patient selection guidelines and DUE for drotrecogin alfa
(activated). Formulary 2002;S1-S15.
Rihn TL, Vanscoy GJ. Combination antithrombotic therapy in acute myocardial infarction. Am J
Health-Syst Pharm 2002;59:1882-85.
Groce JB, Vanscoy GJ, Gainor C. Anticoagulant bridging therapy: Prosthetic heart valves, labeling
changes, and limiting liability. Formulary 2002;37:473-75.

Gordon J. Vanscoy
Page 44
Rihn TL, Vanscoy GJ. Can lytic outcomes in MI be further optimized with LMWHS? Formulary 2002;
37 (Suppl): 1-12.
Vanscoy GJ, Devlin J, Ponzillo, J, Kuhl DA. Implementing guidelines for drotrecogin alfa (activated):
Three perspectives. P&T 2002; October (Suppl): 1-15.
Rihn TL, Vanscoy GJ. Anticoagulant bridging and prosthetic heart valves. Bulletin 2002;544-546.
Vanscoy GJ, Rihn TL, Koerner PH. Tenecteplase: Innovative fibrinolysis for ST-segment elevation
myocardial infarction (STEMI). P&T 2003;28:20-30.
Deitelzweig S, Vanscoy GJ, Niccolai CS, Rihn TL. Venous thromboembolism prevention with LMWHs
in medical and orthopedic surgery patients. Ann Pharmacother 2003;37:402-11.
Gainor C, Niccolai CS, Vanscoy GJ. Pharmacologic and liability considerations of therapeutic
interchange with low-molecular weight heparins. Hosp Pharm 2003;38:652-658.
Vanscoy GJ, McCune JS, Rihn TL. Erythropoietic growth factors in oncology-associated anemia:
Molecules to formulary 2004. Formulary 2004;39(3):S1-S12.
Vanscoy GJ, Rihn TL, Koerner PK, et al. Erythropoietic growth factors in oncology-associated anemia:
Contrasting perspectives on guidelines. Formulary 2004;39(4):S1-S15.
Vanscoy GJ. The inevitability of change. Pharmacotherapy 2004;24(8):101S-102S.
Bussey H, Francis J, and the Heparin Consensus Group. Heparin overview and issues.
Pharmacotherapy 2004;24(8):103S-107S.
Francis J, Groce J, and the Heparin Consensus Group. Challenges in variation and responsiveness of
unfractionated heparin. Pharmacotherapy 2004;24(8):108S-119S.
Deitelzweig S, Groce J, and the Heparin Consensus Group. Anticoagulant prophylaxis in medical
patients: An objective assessment. Pharmacotherapy 2004;24(8):120S-126S.
Nutescu E, Singh-Khalsa M, and the Heparin Consensus Group. Treatment of venous thromboembolism:
Challenging the unfractionated heparin standard. Pharmacotherapy 2004;24(8): 127S-131S.
Rihn TR, Diez J, and the Heparin Consensus Group. Unfractionated heparin in cardiology: Redefining
the standard of practice. Pharmacotherapy 2004;4(8):132S-141S.
Dobesh P, and the Heparin Consensus Group. Unfractionated heparin nomograms: Road maps to where?
Pharmacotherapy 2004;24(8):142S-145S.
Niccolai CS, Hicks RW, Oertel L, Francis J, and the Heparin Consensus Group. Unfractionated heparin:
Focus on a “high-alert” drug. Pharmacotherapy 2004;24(8):146S-155S.
Oertel L, and the Heparin Consensus Group. Unfractionated heparin: A nursing dilemma.
Pharmacotherapy 2004;24(8):156S-160S.

Gordon J. Vanscoy
Page 45
Dobesh P, and the Heparin Consensus Group. Economics of unfractionated heparin: Beyond acquisition
cost. Pharmacotherapy 2004;24(8):161S-164S.
Vanscoy GJ. Comments on clinical and economic comparison of epoetin alfa and darbepoetin alfa.
Current Medical Research and Opinion 2004;20:1459-1461.
Vanscoy GJ, Fortner F, Smith R, Weber R, Rihn TL. Preventing chemotherapy-induced nausea and
vomiting: The economic implications of choosing antiemetics. Community Oncology 2005;2(2):127-
132.
INVITED PAPERS
Vanscoy GJ, Gyi F. A new era in warfarin therapy. US Pharm 1988;13(4):424-430.
Vanscoy GJ. Time management: Put more efficiency in your busy routine. Pharm Econ 1989;2(3):6.
Vanscoy GJ. Set objectives for your pharmacy's success. Pharm Econ 1990;3(3):7.
Vanscoy GJ, Baldini C. Fluconazole. APHA Pharmacy Update 1991;2(1);10-11.
Vanscoy GJ. Drug information at your fingertips. IAIMS Update 1992;3(4):1-2.
Schlicht JR, Vanscoy GJ. Therapeutic monitoring of oral anticoagulants: The INR. Alleg
County Med Soc Bulletin 1993;82:146-7.
Vanscoy GJ. Proper terminology important for interpreting the international normalized ratio [letter
reply]. Hosp Pharm 1993;28(10):1027.
Vanscoy GJ. GUSTO aftermath: Challenge lies in developing practice guidelines. Hosp Formul
1994;Feb(suppl):1-8.
Vanscoy GJ. Pharmacoeconomics and institutional practice: A cognitive opportunity for pharmacy.
California J Hosp Pharm 1994;6:12-13.
Vanscoy GJ. Drug information: Responding to current and future needs. Pharmaguide to Hospital
Medicine 1995;8(3).
AMCP Residency Task Force Members. Draft criteria for residency programs in managed care
pharmacy. J Managed Care Pharm 1997;3(3):363-71.
Vanscoy GJ. Critical pathways to tomorrow’s pharmacy practice. Pharm Manag Advisor 1997:10-11.
Vanscoy GJ. Not all important information is published (editorial). Drug Benefit Trends 1997;9(8):30.
Rihn TL, Tiefenbrun AJ, Vanscoy GJ. Optimizing the acute coronary syndrome formulary: Balancing
costs and quality. Pharm Prac News March 2001:S1-S12.

Gordon J. Vanscoy
Page 46
Vanscoy GJ, Rihn TL, Koerner PH. Guidelines and drug use evaluation for treatment of severe sepsis
with drotrecogin alfa (activated). March 2002:10-13.
Rihn TL, Vanscoy GJ. Anticoagulant bridging and prosthetic heart valves. Bulletin of the Allegheny
County Medical Society October 2002:544-546.
Vanscoy GJ, Rihn TL, O’Neill CK. Optimizing Erythropoietic Growth Factor Formulary Management:
Interchange Opportunities. Formulary 2005;40(S1):S1-S16.
Adamson R, Baribeault D, Lew I, Vanscoy GJ. Contemporary Growth Factor Management: Three
Institutional Perspectives. Hosp Pharm (Therapeutic Insights and Review Issue) February 2006:1-16.
Dagger W, Vanscoy GJ, Spinler S, Vondracek T, Bussey H. Update on the 2004 ACCP/Chest Guidelines
for Antithrombotics. Ann Pharmacother 2006. Submitted.
OTHER PAPERS
Vanscoy GJ. Erythropoietin approved for anemia of chronic renal disease. Pharmacy Consult
1990;1(1):4-5.
Vanscoy GJ, Baldini C. Fluconazole: An advanced antifungal? Pharmacy Consult 1990;1(2):1-2.
Vanscoy GJ, Krause JR. INR? PT? How much warfarin is enough? Pharmacy Consult 1991;2(2);6-7.
Vanscoy GJ. New therapeutic ranges for warfarin therapy: Less drug is better. Pharmacy Consult
1992;3(2):1-4.
Vanscoy GJ. Warfarin therapeutic ranges reduced. ETSAMI Update 1993;2(1):1-3.
Vanscoy GJ. Biostatistical concepts: Preparing for GUSTO. ETSAMI Update 1993;2(2):1-4.
Vanscoy GJ, Davis S. Drug information activities: 1993. ASHP SPG Newsletter 1993 Mar:1-5.
McCarthy M*, Vanscoy GJ. Dipyridamole: A second-line adjunct of a costly placebo? Pharmacy
Consult 1994;5(2):1-4.
Vanscoy GJ, Davis S. Strategic planning and MCM events. ASHP SPG Newsletter 1993 Nov:1-7.
Vanscoy GJ, Rihn TL. Antidysrhythmic use in AMI. ETSAMI Update 1994;3(1):1-3.
Vanscoy GJ, Schwartz JS, Lee T. Health Care Economics. UPMC Continuing Education Series 1994
Mar:1-28.
Vanscoy GJ. ASHP residencies: Drug information. Opportunities '94 1994:20.
Vanscoy GJ. GUSTO one year update. ETSAMI Update 1994;3(1):1-4.

Gordon J. Vanscoy
Page 47
Vanscoy GJ. The evolution of drug informatics. Common Goals: Hospital Shared Systems
1994;10:24-25.
Vanscoy GJ, O’Toole E. Pre-surgical discontinuation of aspirin, NSAIDs. UPMC Physician 1994;3:9.
Vanscoy GJ. Pharmacy specialties: First a residency, then a career. Drug information. Opportunities
'95 1995:20.
Mehta U*, Vanscoy GJ. Improved anticoagulation: A protocol approach to heparin dosing. Pharmacy
Consult 1995;5:1-5.
Rihn TL, Vanscoy GJ. EPILOG-halted: Evolving role of abciximab in acute coronary syndromes. New
Frontiers in Antiplatelet Therapy 1996;1(1):1-4.
Vanscoy GJ. Opportunity Rx: Prevent 40,000 strokes and save 600 million. New Frontiers in Therapy
1996;1(1):1-3.
Rihn TL, Vanscoy GJ. Economic evaluation of abciximab (ReoPro). New Frontiers in Therapy
1996;1(2):1-4.
Verbanac J, Vanscoy GJ. The emerging role of low molecular weight heparins. New Frontiers in
Therapy 1996;1(2):4-7.
Vanscoy GJ, Ryan M. AHA guidelines on the use of thrombolytics in the treatment of stroke. Horizons
in Antithrombosis 1996:3-4.
Vanscoy GJ. Bottom of therapeutic INR range identified. Horizons in Antithrombosis 1996:5.
Rihn TL, Vanscoy GJ. Reteplase: A new plasminogen activator. Horizons in Antithrombosis 1996:1-3.
Vanscoy GJ, Rihn TL. Frontiers in antiplatelet and anticoagulant therapy. 1996 ACCP Annual Meeting
Symposia Highlights 1996:1-4.
Oertel LB, Vanscoy GJ. Credentialing of anticoagulation providers. Anticoagulation Forum
1997;3(2):5.
Vanscoy GJ, Rihn TL. Expanded labeling for abciximab. New Frontiers in Antithrombosis: Acute
Coronary Syndromes 1998;3(1):1-2.
Rihn TL, Vanscoy GJ. Low-molecular weight heparin in unstable angina: The ESSENCE trial. New
Frontiers in Antithrombosis: Acute Coronary Syndromes 1998;3(1):2-3.
Hansen S, Vanscoy GJ. Probucol shows promise in preventing restenosis. New Frontiers in
Antithrombosis: Acute Coronary Syndromes 1998;3(1):4-5.
Vanscoy GJ, Rihn TL. GUSTO III: Final results. Horizons in Antithrombosis March 1998:1-2.

Gordon J. Vanscoy
Page 48
Rihn TL, Vanscoy GJ. Neuroprotective drugs in the treatment of stroke. Horizons in Antithrombosis
March 1998:4-5.
Vanscoy GJ. Anticoagulation provider credentialing progress. Anticoagulation Forum 1998;3(4):1.
Vanscoy GJ, Rihn TL. Peripheral arterial occlusion: Managing the urokinase shortage – clinical and
economic alternative. University of Pittsburgh School of Pharmacy Continuing Education Home-
Study Series 1999;Apr:1-20.
Rihn TL, Vanscoy GJ. Weight-adjusted t-PA dosing reduces ICH risk. Horizons in Antithrombosis
March 1999:1-2.
Rihn TL, Vanscoy GJ. National registry of myocardial infarction: A performance measurement tool
approaching the millennium. Horizons in Antithrombosis March 1999:2-4.
Vanscoy GJ, Rihn TL. 1999 frontiers in myocardial perfusion. Horizons in Antithrombosis March
1999:5-7.
Vanscoy GJ, Rihn TL. Formulary comparison of GP IIb/IIIa blockers. New Frontiers in
Antithrombosis: Acute Coronary Syndromes 1999:3;1-8.
Rihn TL, Vanscoy GJ. The EPISTENT trial: Evolution of a new standard of practice. New Frontiers in
Antithrombosis: Acute Coronary Syndromes 1999:3;3-4.
Vanscoy GJ, Rihn TL. TIMI 14: IIb/IIIa blockers enhance lytic effects. New Frontiers in
Antithrombosis: Acute Coronary Syndromes 1999:3;4-5.
Rihn, TL, Vanscoy GJ. Hospital Pharmacy for the 21 st century: Transitioning your
department/homestudy educational program. University of Pittsburgh School of Pharmacy Continuing
Education Home-Study Series 2000;Apr:1-16.
Vanscoy GJ, Rihn TL. Acute coronary syndromes: Differentiation of glycoprotein IIb/IIIa blockers.
ASHP Midyear Clinical Meeting Highlights March 2001:33-36.
Vanscoy GJ, Rihn TL. Abciximab proven superior to tirofiban in PCI. New Frontiers in
Antithrombosis 2001:4(1)1-4.
Vanscoy GJ, Rihn TL, Groce JB. Therapeutic interchange: A consensus panel’s view of LMWHs. Value
in Thrombosis Management 2001;2(1):1-6.
Rihn TL, Vanscoy GJ. GUSTO IV ACS: Lack of pharmacologic benefit in UA medical stabilization?
New Frontiers in Antithrombosis 2001;4(1):5.
Vanscoy GJ, Rihn TL. TNK-tPA: Single-bolus fibrinolysis. Horizons in Antithrombosis March
2001:1-3.
Groce JB, Vanscoy GJ, Rihn TL. Medenox study with enoxaparin: Effective prevention of DVT in
medically ill patients. Value in Thrombosis Management 2001;2(1):6-7.
Vanscoy GJ, Rihn TL. LMWH durability in ACS. Horizons in Antithrombosis March 2001:5.

Gordon J. Vanscoy
Page 49
Tiefenbrunn AJ, Rihn TL, Vanscoy GJ. Optimizing the acute coronary syndrome formulary. Pharm
Pract News 2001;28(3):S1-S12.
Rihn TL, Vanscoy GJ. Recent GP IIb/IIIa results in PCI. Horizons in Antithrombosis March 2001:4.
Rihn TL, Vanscoy GJ, Koerner PH. Redefining practice in STEMI. Horizons in Antithrombosis
December 2001:1-5.
Vanscoy GJ, Rihn TL. t-PA approved for CVAD occlusion. Horizons in Antithrombosis December
2001:6-7.
Vanscoy GJ, Rihn TL, Koerner PH. ASSENT-3: Redefining practice in STEMI. Value in Thrombosis
Management 2002;3(1):1-5.
Niccolai CS, Vanscoy GJ. Progress in VTE prevention: Part 1-focus on LMWHs. Value in Thrombosis
Management 2002;3(1):6-11.
Vanscoy GJ. Cathflo Activase pharmacy monograph. Preferred Management of Catheter
Thrombosis: Clinical Perspectives on Alteplase Intramed Educational Group. San Francisco, CA,
2003.
Vanscoy GJ. Innovations in anticoagulation: Tempering enthusiasm with evidence. Value in
Thrombosis Management 2003:4(1):1-2.
Vanscoy GJ, Rihn TL, Koerner PH. Contemporary formulary management. Horizons in
Antithrombosis 2003:1-2.
Vanscoy GJ, Rihn TL, Koerner PH. Distilling fibrinolytic consensus guidelines and recommendations.
Horizons in Antithrombosis 2003: 3-4.
Vanscoy GJ, Rihn TL, Koerner PH. Fibrinolytic cost calculator simplifies decision-making. Horizons in
Antithrombosis 2003: 5-6.
Vanscoy GJ, Rihn TL, Koerner PH, Niccolai CS. Synergy trial: Consistent therapy produces results.
Value in Thrombosis Management 2004:5(1):1-2.
Vanscoy GJ, Rihn TL, Koerner PH, Niccolai CS. Challenges in heparin variation and responsiveness.
Value in Thrombosis Management 2004:5(1):1-6.
Vanscoy GJ, Rihn TL, Koerner PH, Niccolai CS. Unfractionated heparin: Focus on a high-alert
medication. Value in Thrombosis Management 2004:5(1):1-4.
Vanscoy GJ. Oncology-associated anemia: Epoetin or darbepoetin? Cancer Support Innovations
2004:1(1): 1-2.
Vanscoy GJ. Optimizing outcomes in chemotherapy-induced neutropenia. Cancer Support
Innovations 2004:1(1): 1-5.

Gordon J. Vanscoy
Page 50
Vanscoy GJ, Rihn TL, Koerner PH. To aliquot or not: This is the question. Horizons in Antithrombosis
2005: 1-2.
Vanscoy GJ, Rihn TL, Koerner PH. 2004 updated fibrinolytic practice guidelines and consensus
recommendations. Horizons in Antithrombosis 2005: 1-4.
Vanscoy GJ, Rihn TL, Koerner PH. New fibrinolytic calculator facilitates decision making. Horizons in
Antithrombosis 2005: 1-3.
Vanscoy GJ, Rihn TL, Koerner PH, Niccolai CS. Contemporary Growth Factor Management. Cancer
Support Innovations 2005:2(1): 1-2.
Vanscoy GJ, Rihn TL, Koerner PH, Niccolai CS. Growth Factors: Operational Efficiency Opportunities.
Cancer Support Innovations 2005:2(1): 1-4.
Vanscoy GJ, Rihn TL, Koerner PH, Niccolai CS. Contemporary Anticoagulant Therapy in Special
Populations. Value in Thrombosis Management 2005:6(2):1-7.
OTHER MEDIA
Pittman DG, Rihn TL, Vanscoy GJ. Treatment trends in acute coronary artery disease (audiorecording).
New York, NY: NCM, 1994.
Vanscoy GJ, Schwartz JS, Lee T. Health care economics (videorecording). Califon, NJ: Synermed,
1994.
Vanscoy GJ, Ho-Kean* A. Anticoagulation to prevent stroke (slide set). Irwin, PA:
UPA. 1996.
Vanscoy GJ, Rihn TL. Acute coronary syndromes: Focus on GP IIb/IIIa blockers (real audio Internet
CPE program). www.upa-llc.com. 1998.
Vanscoy GJ, Rihn TL. Peripheral arterial occlusion: Managing the urokinase shortage – clinical and
economic alternative. (Internet CPE program). www.pharmacy.pitt.edu/ce/pao.html. 1999.
Vanscoy GJ, Rihn TL. Acute coronary syndromes: Differentiation of GP IIb/IIIa blockers (real audio
Internet CPE program). www.upa-llc.com. 2000.
Vanscoy GJ, Rihn TL. Defusing thrombotic risk with an evidence-based LMWH formulary. (Internet
CPE program). www.upa-llc.com. 2000.
Vanscoy GJ, Rihn TL. Are IIb's me II’s? (real audio Internet CPE program). www.upa-llc.com. 2001.
Vanscoy GJ, Rihn TL. Consensus on LMWH differentiation: Issues and evolving evidence (Internet
CPE program). www.upa-llc.com. 2001.
Vanscoy GJ, Rihn TL. Interrupting the sepsis cascade: Innovation in biotechnology. (Internet CPE
program). www.upa-llc.com. 2001.

Gordon J. Vanscoy
Page 51
Vanscoy GJ, Rihn TL. Fibrinolysis: Peripheral arterial and catheter occlusion. (Internet CPE program).
http://www.cecity.com/upa/fpact/disclaim_pitt.htm. 2001.
Vanscoy GJ, Rihn TL. Integrating new fibrinolytic findings into AMI reperfusion and combination
therapy (Internet CPE program). http://www.cecity.com/upa/infarct/disclaim.htm. 2001.
Vanscoy GJ, Rihn TL. Maximizing biotech value in sepsis management. (Internet CPE program).
http://www.upa-llc.com/ce_sepsis.htm. 2002.
Vanscoy GJ, Rihn TL. Therapeutic interchange: Application to LMWHs. (Internet CPE program).
http://www.upa-llc.com/ce_lmwh_thera.htm. 2002.
Vanscoy GJ, Rihn TL. LMWH horizons: New uses, new evidence, new agents. (Internet CPE program).
http://www.upa-llc.com/ce_lmwh.htm. 2002.
Vanscoy GJ, Rihn TL. Can lytic outcomes in MI be further optimized with LMWHs? (CD-ROM
video/slide program). Monroeville, Pennsylvania: UPA. 2002.
Vanscoy GJ, Rihn T. Limiting liability in anticoagulant bridging [essay]. American College of
Cardiology Web Site ACCardio. October 2002. Available at
http://www.accardio.org/hottopics/article.asp?PaperID=35. Accessed October 21, 2002.
Vanscoy GJ, Boucher B, Mann H, Rihn TL. Integrating evolving evidence into sepsis management:
Maximizing value with drotrecogin alfa. (CD-ROM video). Monroeville, Pennsylvania: UPA. 2003.
Vanscoy GJ, Rihn TL. Fibrinolytic economic assessment tool-kit. (CD-ROM calculator). Monroeville,
Pennsylvania: UPA. 2003.
Vanscoy GJ, Rihn TL. Erythropoietic growth factor economic calculator. (Internet tool). Available at
http://upa-llc.com/newsletter.htm. 2004.
Vanscoy GJ, Rihn TL. Challenging the heparin paradigm in VTE: the evidence-based role of LMWHs.
(Internet CPE program). http://www.cecity.com/upa/vte_2004/disclaim.htm. 2004.
Vanscoy GJ, Rihn TL. Making informed formulary decisions: Focus on fibrinolytics. (Internet CPE
program). http://www.cecity.com/pitt/fibrinolytics/disclaim_pitt.htm. 2004.
Vanscoy GJ, Rihn TL. Challenging the heparin paradigm in cardiology: the evidence-based role of
LMWHs. (Internet CPE program). http://www.cecity.com/upa/cardiology/disclaim.htm 2004.
Vanscoy GJ, Rihn TL. Assessing the value of erythropoietic growth factors in oncology-associated
anemia: consensus and controversies (Internet CPE program).
http://www.cecity.com/upa/anemia2004/disclaim.htm. 2004.
Vanscoy GJ, Rihn TL. Fibrinolytic economic assessment tool-kit. (Internet tool). Available at http://
upa-llc.com/newsletter.htm. 2004.
Vanscoy GJ, Rihn TL. Optimizing outcomes in chemotherapy-induced neutropenia:

Gordon J. Vanscoy
Page 52
Synchronized CSF innovation. (Internet CPE program).
http://www.cecity.com/upa/neutropenia/disclaim.htm. 2004.
Vanscoy GJ, Rihn TL. Introduction to acute decompensated heart failure and contemporary therapy.
(Internet CPE program). http://www.cecity.com/upa/heart_failure/disclaim.htm. 2005.
Vanscoy GJ, Rihn TL. Erythropoietic growth factor economic calculator. (Internet tool). Available at
http://www.upa-llc.com/popup_EGF%20Econ%20Calculator.htm. 2005.
Vanscoy GJ, Rihn TL. Fibrinolytic economic assessment tool-kit. (Internet tool). Available at http://
upa-llc.com/popup_toolkit.htm. 2005.
Vanscoy GJ. Consensus on contemporary UFH issues: Medication errors with heparins. Webcast
available at www.thrombosisclinic.com. 2005.
ABSTRACTS & SCIENTIFIC PRESENTATIONS AT MEETINGS
SCIENTIFIC PRESENTATIONS
Students* under my direction are indicated by an asterisk.
Vanscoy GJ, Giudici RA, Mattei TJ. Development of a model for predicting pharmacy personnel
requirements. Twentieth Annual American Society of Hospital Pharmacists Midyear Clinical Meeting.
New Orleans, Louisiana. December 4, 1985.
Vanscoy GJ, Schneider SM Michelson EA. Amanita Phalloides poisoning: Mechanism of cimetidine
protection. Platform presentation. University Association for Emergency Medicine Annual Meeting.
Cincinnati, Ohio. June 17, 1988.
Schneider SM, Vanscoy GJ. Penicillin and cimetidine in alpha-amanitin toxicity in mice. Platform
presentation. American Academy of Clinical Toxicology Annual Scientific Meeting. Baltimore,
Maryland. October 3, 1988.
Vanscoy GJ, Schneider SM. Cimetidine and ascorbic acid in the treatment of alpha-amanitin toxicity in
mice. Poster presentation. American Academy of Clinical Toxicology Annual Scientific Meeting.
Baltimore, Maryland. October 3, 1988.
Stoehr GP, Vanscoy GJ, Michelson EA. University-based contractual clinical pharmacy services. Poster
presentation. Twenty-third Annual American Society of Hospital Pharmacists Midyear Clinical Meeting.
Dallas, Texas. December 6, 1988. Pennsylvania Society of Hospital Pharmacists Midwinter Conference
X. Pittsburgh, Pennsylvania. March 2, 1989.
Vanscoy GJ, McAuley J. Exaggerated warfarin response: A case report. Poster presentation.
Pennsylvania Society of Hospital Pharmacists Midwinter Conference X. Pittsburgh, Pennsylvania. March
2, 1989. American Academy of Clinical Toxicology Annual Scientific Meeting, American Academy of
Clinical Toxicology Annual Meeting. Atlanta, Georgia. October 4, 1989.
Schneider SM, Vanscoy GJ, Michelson EA. Failure of n-acetylcysteine to reduce alpha-amanitin toxicity.
Poster presentation. American Academy of Clinical Toxicology Annual Scientific Meeting. Atlanta,
Georgia. October 4, 1989.

Gordon J. Vanscoy
Page 53
Schneider SM, Vanscoy GJ, Michelson EA. Combination treatment with cimetidine, penicillin and
ascorbic acid for alpha-amanitin toxicity. Platform presentation. University Association for Emergency
Medicine Annual Meeting. Toronto, Canada. June 18, 1989.
Vanscoy GJ, Giudici RA. Pharmacy workload forecasting: Validation of the PHASU model for
predicting pharmacy personnel requirements. Pennsylvania Society of Hospital Pharmacists Midwinter
Conference X. Pittsburgh, Pennsylvania. March 2, 1989.
Vanscoy GJ, Coccodrilli KR, Stoehr GP. A student-centered approach for teaching drug information and
literature evaluation. Poster presentation. American Association of Colleges of Pharmacy Annual
Meeting. Boston, Massachusetts. July 10, 1991.
Stablein * AM, Vanscoy GJ, Coccodrilli KR, Schlicht JR. Drug information internship: Valuable
cognitive training for tomorrow's pharmacists. Poster presentation. American Society of Hospital
Pharmacists Midyear Clinical Meeting. New Orleans, Louisiana. December 9, 1991.
Shaughnessy AF, Schlicht * JR, Vanscoy GJ. Survey and evaluation of newsletters marketed to family
practice physicians. Twenty-fifth Annual Spring Conference of the Society of Teachers of Family
Medicine. St. Louis, Missouri. April 29, 1992.
Verrico * M, Vanscoy GJ. Computer support in diagnosis of drug-induced disease: Phenytoin toxicity.
Fourteenth Annual Undergraduate Research Seminar. Morgantown, West Virginia. October 9, 1992.
Horton * J, Vanscoy GJ. Assessing the impact of published standards on the treatment of atrial fibrillation.
Fourteenth Annual Undergraduate Research Seminar. Morgantown, West Virginia.
October 9, 1992.
Vanscoy GJ, Schlicht * JR, Miller RA, Giuse NB. Computer-assisted diagnosis of drug induced diseases.
Twenty-seventh Annual ASHP Midyear Clinical Meeting. Orlando, Florida. December 9, 1992.
Coccodrilli KR, Markind JE, Vanscoy GJ. Design and implementation of a multi-hospital staff
development program in drug information at a university medical center. Twenty-seventh Annual ASHP
Midyear Clinical Meeting. Orlando, Florida. December 9, 1992.
Kendrach * MG, Bouzos CG, Vanscoy GJ. Development of a LAN-based multi-institutional drug
information database. Twenty-seventh Annual ASHP Midyear Clinical Meeting. Orlando, Florida.
December 9, 1992.
Barron * R, Vanscoy GJ. Natural products and the athlete: Facts and folklore. Twenty-eighth Annual
ASHP Meeting. Denver, Colorado. June 6, 1993.
Coley KC, Kendrach MG, Vanscoy GJ. Residency portfolio: A tool for self-directed development. Poster
presentation. Twenty-eighth Annual ASHP Midyear Clinical Meeting. Atlanta, Georgia. December 7,
1993.
Vanscoy GJ. Drug informatics. Twenty-eighth Annual ASHP Midyear Clinical Meeting. Atlanta,
Georgia. December 8, 1993.

Gordon J. Vanscoy
Page 54
Vanscoy GJ. Paperless drug information center. Twenty-eighth Annual ASHP Midyear Clinical Meeting.
Atlanta, Georgia. December 8, 1993.
Coley KC, Kendrach MG, Vanscoy GJ. Residency portfolio: A tool for self-directed development
(DIRF). Twenty-eighth Annual ASHP Midyear Clinical Meeting. Atlanta, Georgia. December 8, 1993.
Vanscoy GJ. Impacting acute myocardial infarction. Twenty-eighth Annual ASHP Midyear Clinical
Meeting. Atlanta, Georgia. December 9, 1993.
Vanscoy, GJ. Global utilization of streptokinase and t-PA for occluded coronary arteries trial results and
implications: What now? Twenty-eighth Annual ASHP Midyear Clinical Meeting. Atlanta, Georgia.
December 9, 1993.
Gajewski LK, Vanscoy GJ. Extending the mission of drug information: From database to bedside.
Thirteenth Annual Eastern States Conference for Pharmacy Residents and Preceptors. Baltimore,
Maryland. April 22, 1994.
Vanscoy GJ. Critical pathways approach to therapeutic management. University Hospital Consortium
Pharmacy Advisory Committee Annual Meeting. Miami, Florida. December 3, 1994.
Vanscoy GJ. The future of drug information: A CAMIPR perspective. Twenty-ninth Annual ASHP
Midyear Clinical Meeting Abstracts. Miami, Florida. December 5, 1994.
Gajewski LK, Vanscoy GJ, Dean J, Bouzos C. IRxBase: A computerized LAN-based investigational drug
information database. Poster presentation. Twenty-ninth Annual ASHP Midyear Clinical Meeting.
Miami, Florida. December 7, 1994.
Vanscoy GJ, Kelley CL, Lowe JC. Anchoring pharmacy’s future through cognitive role credentialling.
Poster presentation. Twenty-ninth Annual ASHP Midyear Clinical Meeting. Miami, Florida.
December 7, 1994.
Vanscoy GJ. Critical pathways: Pharmacotherapy of myocardial infarction. Twenty-ninth Annual ASHP
Midyear Clinical Meeting. Miami, Florida. December 8, 1994.
Mehta U, Vanscoy GJ. Implementation of an institution-wide weight-based heparin dosing protocol.
Fourteenth Annual Eastern States Conference for Pharmacy Residents and Preceptors. Baltimore,
Maryland. April 29, 1995
Wagner T, Vanscoy GJ, Baum C, Dunbar-Jacob J, et al. Medication compliance assessment in transplant
recipients. Fourteenth Annual Eastern States Conference for Pharmacy Residents and Preceptors.
Baltimore, Maryland. April 29, 1995.
Vanscoy GJ, Boyer A. Critical pathways to impacting outcomes: Enhancing rational prescribing and
formulary management. Managed Health Care Congress Northeast Meeting. The National Managed
Health Care Congress. New York, New York. November 13, 1995.
Vanscoy GJ. Pharmacoepidemiology: Research methods and outcomes applications. Thirtieth Annual
ASHP Midyear Clinical Meeting. Las Vegas, Nevada. December 5, 1995.

Gordon J. Vanscoy
Page 55
Vanscoy GJ. Medication compliance in organ transplant recipients. Thirtieth Annual ASHP Midyear
Clinical Meeting Managed Care Pearls. December 5, 1995.
Vanscoy GJ. Critical pathways to impacting outcomes: Enhancing rational prescribing and formulary
management. Eighth Annual AMCP Meeting. San Francisco, California. May 9, 1996.
Ho-Kean A., Vanscoy GJ. Development of a biotechnology drug database: Biotech MediSource.
Fifteenth Annual Eastern States Conference for Pharmacy Residents and Preceptors. Baltimore,
Maryland. April 26, 1996.
Vanscoy GJ, Wagner TA, Nissen JC, Gajewski LK, Niccolai CS, Callas N. StadtCare Intervent ® :
Development and implementation of a computerized disease management intervention documentation
system. Eighth Annual AMCP Meeting. San Francisco, California. May 10, 1996.
Gleason PP, Vanscoy GJ, Vitale F, Shiffman S, Juhl RP. Development and implementation of a national
smoking cessation specialist certificate program. Poster Presentation. ACCP 1997 Annual Meeting.
Phoenix, Arizona. November 10, 1997.
Vanscoy GJ, Shacker TW. Treating HIV and AIDS: New drug profiles and clinical data - an evolving
armamentarium. Ninth Annual AMCP Meeting. New Orleans, Louisiana. May 9, 1997.
Gajewski LD, Melbourne K, Grimone A, Vanscoy GJ. Characterization of rash with indinavir. Poster
Presentation. Ninth Annual AMCP Meeting. New Orleans, Louisiana. May 9, 1997.
Ho-Kean A, Gajewski LD, Vanscoy GJ, Niccolai CS. Prescriber-targeted education process. Poster
Presentation. Ninth Annual AMCP Meeting. New Orleans, Louisiana. May 9, 1997.
Niccolai CS, Ritzman CL, Gajewski LD, Vanscoy GJ. Designed pharmacist-initiated clinical
interventions. Poster Presentation. Ninth Annual AMCP Meeting. New Orleans, Louisiana.
May 9, 1997.
Ritzman CL, Gajewski LD, Vanscoy GJ. Development of an HIV/AIDS pharmacy certification program.
Poster Presentation. Ninth Annual AMCP Meeting. New Orleans, Louisiana. May 9, 1997.
Vanscoy GJ. Innovations in residency programs in managed care pharmacy: The residency portfolio as a
learning tool. Ninth Annual AMCP Meeting. New Orleans, Louisiana. May 10, 1997.
Vanscoy GJ, Rock W. Credentialing of anticoagulation providers: A proposed model. The
Anticoagulation Forum. San Antonio, Texas. May 16, 1997.
Castiglione B, Vanscoy GJ. Economic analysis of pharmacy interventions in HIV/AIDS. Poster
Presentation. Tenth Annual AMCP Meeting. Philadelphia, Pennsylvania. May 1, 1998.
Lewis SM, Gajewski LK, Ho-Kean A, Vanscoy GJ. Managing the indinavir/nevirapine interaction via
U.S. prescriber education on dosing strategies. Twelfth World AIDS Conference. Geneva, Switzerland.
June 29, 1998.
Lewis SM, Ho-Kean A, Gajewski LK, Vanscoy GJ. Effectiveness of a systematic educational approach
to alter suboptimal dosing of indinavir. Twelfth World AIDS Conference. Geneva, Switzerland.

Gordon J. Vanscoy
Page 56
June 29, 1998.
Nissen JC, Gajewski LK, Grimone AJ, Vanscoy GJ. Nationwide protease inhibitor adherence program.
Twelfth World AIDS Conference. Geneva, Switzerland. July 1, 1998.
Miller MJ, Harrison DL, Lewis SM, Kroner BA, Castiglione B, Vanscoy GJ. Estimating the relative
impact of product variability on the costs and consequences of outpatient anticoagulation. Thirty-third
ASHP Midyear Clinical Meeting. Las Vegas, Nevada. December 8, 1998.
Birescik JL*, Miller MJ, Rihn T, Castiglione B, Vanscoy GJ. Assessing patient knowledge about
hepatitis C and its treatment: questionnaire development. Poster Presentation. ASHP Midyear Clinical
Meeting. Las Vegas, Nevada. December 8, 1998.
Raval P*, Miller MM, Gajewski-Verbanac L, Vanscoy GJ. Selecting primary treatment for active and
maintenance therapy in mild to moderate ulcerative colitis: An economic decision model. APhA Annual
Meeting and Exposition. San Antonio, Texas. March 15, 1999.
Peris A, Penatzer L, Rihn TL, Vanscoy GJ. Pharmacy initiated interventions in the management of
schizophrenia. Poster Presentation. Eleventh Annual AMCP Meeting, Minneapolis, Minnesota. April 28,
1999.
Folk P, Nissen J, Lynch KJ, Rihn TL, Vanscoy GJ. National pharmacy-based immunosuppressant
adherence program. 1999 NATCO Annual Meeting. Albuquerque, New Mexico. July 24, 1999.
Lynch KL, Castiglione B, Aiken A, Law M, Vanscoy GJ. Pharmacy-initiated national
immunosuppressant adverse event counseling program. 1999 ITNS Annual Meeting. Toronto, Canada.
September 11, 1999.
Gajewski-Verbanac L, Lewis SM, Chrisman C, Rihn T, Hartman T, Vanscoy GJ. Retrospective analysis
of antiretroviral treatment to guidelines in a national correctional base. Poster Presentation. Thirty-ninth
Annual ICAAC Meeting, San Francisco, California. September 27, 1999.
Gajewski-Verbanac L, Lewis SM, Castiglione B, Rihn T, Vanscoy GJ. Financial impact of a prescribertargeted
educational program to optimize dosing of indinavir. Poster Presentation. 1999 AMCP
Educational Conference. Atlanta, Georgia. October 7, 1999.
Rihn, TL, Raval P, Vanscoy GJ. Managing the urokinase shortage: clinical and economic alternatives in
peripheral arterial occlusion. Poster Presentation. ASHP Midyear Clinical Meeting. Orlando, Florida.
December 6, 1999.
Gleason PP, Jones-Barlock A, Schommer J, Vitale F, Vanscoy GJ. Patients’ assessment of pharmacists
smoking cessation counseling. ACCP 2000 Spring Practice and Research Forum. Monterey, California.
April 3, 2000.
Jones-Barlock A, Gleason PP, Vitale F, Vanscoy GJ. National sample of pharmacists’ pharmacotherapy
recommendations for smoking cessation. ACCP 2000 Spring Practice and Research Forum. Monterey,
California. April 3, 2000.

Gordon J. Vanscoy
Page 57
Peris A, Castiglione B, Vanscoy GJ. Health care expenditure in an HMO before and after an exclusive
pharmacy partnership. ISPOR Fifth Annual International Meeting. Arlington, Virginia. May 22, 2000.
Vanscoy GJ, O’Connor T, Hammonds B. Administrative and ethical issues in the provision of continuing
pharmaceutical education. ACPE 9 th Invitational Conference on Continuing Pharmaceutical Education.
Phoenix, AZ. November 3, 2001.
Vanscoy GJ, Rubenstein E, Smith R, Weber R, Rihn TL. Pharmaeconomic analysis of palonosetron in
patients receiving moderately emetogenic chemotherapy. Poster presentation. Thirty-ninth Annual ASHP
Midyear Clinical Meeting. Orlando, Florida. December 8, 2004.
ABSTRACTS
Vanscoy GJ, Giudici RA, Mattei TJ. Development of a model for predicting pharmacy personnel
requirements. Am J Hosp Pharm 1985;42(10):2259.
Schneider SM, Vanscoy GJ, Michelson EA. Amanita phalloides poisoning: Mechanism of cimetidine
protection. Ann Emerg Med 1988;17(1):402-403.
Schneider SM, Vanscoy GJ. Penicillin and cimetidine in alpha-amanitin toxicity in mice. Vet Hum
Toxicol 1988;30:364.
Stoehr GP, Vanscoy GJ, Swanson DJ, Lowe J. Contractual university-based clinical pharmacy services.
Am J Hosp Pharm 1988;45(10):2155.
Vanscoy GJ, Schneider SM. Cimetidine and ascorbic acid in the treatment of alpha-amanitin toxicity in
mice. Vet Hum Toxicol 1988;30:368.
Vanscoy GJ, McAuley * J. Exaggerated warfarin response: A case report. AACT Annual Meeting
Program and Abstracts 1989; PSHP Midwinter Conference X 1989.
Schneider SM, Vanscoy GJ, Michelson EA. Failure of n-acetylcysteine to reduce alpha-amanitin toxicity.
Vet Hum Toxicol 1989;31:359.
Schneider SM, Vanscoy GJ, Michelson EA. Combination treatment with cimetidine, penicillin and
ascorbic acid for alpha-amanitin toxicity. Ann Emerg Med 1989;18:482.
Vanscoy GJ, Giudici RA. Validation of the PHASU model for predicting pharmacy personnel
requirements. PSHP Midwinter Conference X Program and Abstracts 1989;10:9.
Vanscoy GJ, Coccodrilli KR, Stoehr GP. A student-centered approach for teaching drug information and
literature evaluation. Amer J Pharm Ed 1991;55s:140s.
Stablein * AM, Vanscoy GJ, Coccodrilli KR, Schlicht * JR. Drug information internship: Valuable
cognitive training for tomorrow's pharmacists. Twenty-fifth ASHP Midyear Clinical Meeting
Supplemental Abstracts 1991.
Schlicht * JR, Vanscoy GJ, Miller RA, Giuse NB. Enhancement of a computerized database program to
include the ability to differentiate drug-induced diseases. Pharmacotherapy 1992;12(3):259.

Gordon J. Vanscoy
Page 58
Shaughnessy AF, Schlicht * JR, Vanscoy GJ. Survey and evaluation of newsletters marketed to family
practice physicians. Submitted and accepted for presentation. Twenty-fifth Annual Spring Conference
of the Society of Teachers of Family Medicine Program and Abstracts 1992.
Schlicht * JR, Vanscoy GJ, Miller RA, Giuse NB. Computer-assisted diagnosis of drug induced diseases.
Twenty-seventh Annual ASHP Midyear Clinical Meeting Abstracts 1992:326.
Coccodrilli KR, Markind JE, Vanscoy GJ. Design and implementation of a multi-hospital staff
development program in drug information at a university medical center. Twenty-seventh Annual
ASHP Midyear Clinical Meeting Abstracts 1992:326.
Kendrach * MG, Bouzos CG, Vanscoy GJ. Development of a LAN-based multi-institutional drug
information database. Twenty-seventh Annual ASHP Midyear Clinical Meeting Supplemental
Abstracts 1992.
Verrico * M, Vanscoy GJ. Computer support in diagnosis of drug-induced disease: Phenytoin toxicity.
Fourteenth Annual Undergraduate Research Seminar Abstracts 1992:12.
Horton * J, Vanscoy GJ. Assessing the impact of published standards on the treatment of atrial fibrillation.
Fourteenth Annual Undergraduate Research Seminar Abstracts 1992:17.
Kendrach * MG, Bouzos CG, Vanscoy GJ. Development of a LAN-based multi-institutional drug
information database. PSHP Midyear XIV Program and Abstracts 1993;14:11.
Barron * R, Vanscoy. Natural products and the athlete: Facts and folklore. Twenty-eighth Annual
ASHP Meeting Abstracts 1993.
Vanscoy GJ. Drug informatics. Twenty-eighth Annual ASHP Midyear Clinical Meeting Abstracts
1993;SPG-40:81.
Vanscoy GJ. Step 1 - The paperless drug information center. Twenty-eighth Annual ASHP Midyear
Clinical Meeting Abstracts 1993;SPG-41:81.
Coley KC, Kendrach MG, Vanscoy GJ. Residency portfolio: A tool for self-directed development.
Twenty-eighth Annual ASHP Midyear Clinical Meeting Abstracts 1993;DIRF-3:83.
Vanscoy GJ. Impacting acute myocardial infarction. Twenty-eighth Annual ASHP Midyear Clinical
Meeting Abstracts 1993;PI-137:62.
Coley KC, Kendrach MG, Vanscoy GJ. Residency portfolio: A tool for self-directed development.
Twenty-eighth Annual ASHP Midyear Clinical Meeting Abstracts 1993;P-120D:108.
Vanscoy GJ. Global utilization of streptokinase and t-pa for occluded coronary arteries trial results and
implications: What now? Twenty-eighth Annual ASHP Midyear Clinical Meeting Abstracts 1993;PI-
137:62.

Gordon J. Vanscoy
Page 59
Gajewski LK, Vanscoy GJ. Extending the mission of drug information: From database to bedside.
Thirteenth Annual Eastern States Conference for Pharmacy Residents and Preceptor Program and
Abstracts. 1994;64.
Vanscoy GJ. The evolution of drug informatics. Twenty-eighth Annual HPMMA/HHS Health Care
Forum Program and Abstracts 1994;7.
Gajewski LK, Vanscoy GJ, Dean J, Bouzos C. IRxBase: Computerized LAN-based investigational drug
information database. International Pharmaceutical Abstracts. 1994;31:2328.
Vanscoy GJ, Kelley CL, Lowe JC. Anchoring pharmacy’s future through cognitive role credentialling.
International Pharmaceutical Abstracts. 1994;31:2200.
Vanscoy GJ. Critical pathways: Pharmacotherapy of myocardial infarction. International
Pharmaceutical Abstracts. 1994;31:2274.
Vanscoy GJ. Future of drug information: CAMIPR perspective. International Pharmaceutical
Abstracts. 1994;31:2326.
Mehta* U, Vanscoy GJ. Implementation of an institution-wide weight-based heparin dosing protocol.
Fourteenth Annual Eastern States Conference for Pharmacy Residents and Preceptors Abstracts.
1995;111.
Wagner T, Vanscoy GJ, Baum C, Dunbar-Jacob J, et al. Medication compliance assessment in transplant
recipients. Fourteenth Annual Eastern States Conference for Pharmacy Residents and Preceptors
Abstracts. 1995;100.
Ho-Kean A, Vanscoy GJ. Development of a Biotechnology Drug Database: BioTech MediSource.
Fifteenth Annual Eastern States Conference for Pharmacy Residents and Preceptors Abstracts.
1996;21.
Vanscoy GJ, Wagner TA, Nissen JC, Gajewski LK, Niccolai CS, Callas N. StadtCare Intervent:
development and implementation of a computerized disease management intervention documentation
system. AMCP Eighth Annual Meeting Abstracts. 1996;PS14.
Gajewski LD, Melbourne K, Grimone A, Vanscoy GJ. Characterization of rash with indinavir.
J Managed Care Pharm 1997;3(3):296-7.
Ho-Kean A, Gajewski LD, Vanscoy GJ, Niccolai CS. Prescriber-targeted education process.
J Managed Care Pharm 1997;3(3):298.
Niccolai CS, Ritzman CL, Gajewski LD, Vanscoy GJ. Designed pharmacist-initiated clinical
interventions. J Managed Care Pharm 1997;3(3):299.
Ritzman CL, Gajewski LD, Vanscoy GJ. Development of an HIV/AIDS pharmacy certification program.
Ninth Annual AMCP Meeting Program and Abstract Book 1997:329.
Vanscoy GJ, Schacker TW. Treating HIV and AIDS: New drug profiles and clinical data - an evolving
armanmentarium. Ninth Annual AMCP Meeting Program and Abstract Book 1997:42.

Gordon J. Vanscoy
Page 60
Vanscoy GJ. Innovations in residency programs in managed care pharmacy: The residency portfolio as a
learning tool. Ninth Annual AMCP Meeting Program and Abstract Book 1997:272.
Swanson DJ, Castiglione B, Kazmierczak R, Gajewski L, Vanscoy GJ. Intervention and outcomes
opportunities in HIV/AIDS. Ninth Annual AMCP Meeting Program and Abstract Book 1997:192.
Gleason PP, Vanscoy GJ, Vitale F, Shiffman S, Juhl RP. Development and implementation of a national
smoking cessation specialist certificate program. Pharmacotherapy 1997;17(5):1127.
Castiglione B, Gajewski LK, Vanscoy GJ. Cost analysis of pharmacy interventions in HIV/AIDS. Tenth
Annual AMCP Meeting Program and Abstract Book 1998;288.
Lewis SM, Ho-Kean A, Gajewski LK, Vanscoy GJ. Effectiveness of a systematic educational approach
to alter suboptimal dosing of indinavir. Twelfth World AIDS Conference Geneva Conference Record
and Abstract Book 1998;71.
Lewis SM, Gajewski LK, Ho-Kean A, Vanscoy GJ. Managing the indinavir/nevirapine interaction via
U.S. prescriber education on dosing strategies. Twelfth World AIDS Conference Geneva Conference
Record and Abstract Book 1998;92.
Nissen JC, Gajewski LK, Grimone AJ, Vanscoy GJ. Nationwide protease inhibitor adherence program.
Twelfth World AIDS Conference Geneva Conference Record and Abstract Book 1998;586.
Ho-Kean A, Gajewski LK, Lewis SM, Vanscoy GJ, Archibeque E. Development of nationwide
HIV/AIDS herbal formulary. Twelfth World AIDS Conference Geneva Conference Record and
Abstract Book 1998;1069.
Raval PJ*, Miller MJ, Gajewski LK, Vanscoy GJ. Selecting primary treatment for active and
maintenance therapy in mild to moderate ulcerative colitis: An economic decision analysis (abstract).
Journal of the American Pharmaceutical Association 1998;39(2):270-1.
Miller MJ, Harrison DL, Lewis SM, Kroner BA, Castiglione B, Vanscoy GJ. Estimating the relative
impact of product variability on the costs and consequences of outpatient anticoagulation. ASHP
Midyear Clinical Meeting. 1998;33(Dec):P-210E.
Rihn, TL, Raval P, Vanscoy GJ. Managing the urokinase shortage: clinical and economic alternatives in
peripheral arterial occlusion. ASHP Midyear Clinical Meeting. 1998;33(Dec):P-11D.
Gajewski-Verbanac L, Lewis S, Chrisman C, Rihn, T, Hartman T, Vanscoy GJ. Retrospective analysis of
antiretroviral treatment to guidelines in a national correctional base. Thirty-ninth Interscience
Conference on Antimicrobiral Agents and Chemotherapy (ICAAC). 1999;482.
Gleason PP, Jones-Barlock A, Schommer J, Vitale F, Vanscoy GJ. Patients’ assessment of pharmacists
smoking cessation counseling. ACCP 2000 Spring Practice and Research Forum. 2000;345.
Jones-Barlock A, Gleason PP, Vitale F, Vanscoy GJ. National sample of pharmacists’ pharmacotherapy
recommendations for smoking cessation. ACCP 2000 Spring Practice and Research Forum.
2000;345.

Gordon J. Vanscoy
Page 61
Peris A, Castiglione B, Vanscoy GJ. Health care expenditure in an HMO before and after an exclusive
pharmacy partnership. ISPOR Fifth Annual International Meeting. Value in Health. 2000;3(2):155.
Barlock AJ, Gleason PG, Schommer J, Vitale F, Vanscoy GJ, Cornelius JR, Juhl RP. Pharmacists’
recommendations for smoking cessation pharmacotherapy. Drug and Alcohol Dependence Supplement
to the 63 rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2001;63:S75.
Vanscoy GJ, Rubenstein E, Smith R, Weber R, Rihn TL. Pharmaeconomic analysis of palonosetron in
patients receiving moderately emetogenic chemotherapy. 39th ASHP Midyear Clinical Meeting. 2004
(Dec): P390E.
Schwartzberg LS, Vanscoy GJ. Cost comparison of palonosetron to short-acting serotonin receptor
antagonists for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. 2005
Chicago Supportive Oncology Conference. 2005 (Oct): PA14.
GRANTS AND OTHER PROPOSALS FUNDED
Cimetidine use in amanita phalloides poisoning: Mechanism of hepatoprotection. Smith Kline & French
Laboratories Young Investigators Grant, Principal Investigator. 1987-1988. $10,000.
Cimetidine, penicillin and ascorbic acid use in amanita phalloides poisoning: The basis of a rational
treatment strategy. Montefiore Hospital, Department of Medicine, General Research Funds, Co-Principal
Investigator. 1986-1990. $15,000.
Amanita phalloides poisoning: Mechanism of cimetidine protection. University Association of
Emergency Medicine, Co-Principal Investigator. 1988. $1,000.
Anticoagulant therapy: Current concepts and controversies. DuPont Pharmaceuticals, Educational Grant,
Principal Developer and Program Administrator. 1988. $2,348.
Biochemical, histopathologic and survival effects of cimetidine combinations on alpha-amanitin toxicity:
An animal model. Smith Kline & French Investigators Award, Principal Investigator. 1986-1990.
$10,000.
Establishing a model drug information and pharmacoepidemiology center. The Merck Foundation, Co-
Principal Investigator. 1990-1993. $90,000.
Evolving therapeutic strategies in acute myocardial infarction. Genentech Inc., Educational Grant,
Developer and Program Administrator. 1991-1993. $100,000.
Enhancement of QMR to diagnose theophylline toxicity. University of Pittsburgh Section of Medical
Informatics, Co-Principal Investigator. 1992. $1,000.
Natural products and the athlete. Upjohn Co., Principal Investigator. 1992-1993. $500.
Extending access to Tomes ® . University of Pittsburgh Department of Environmental and Occupational
Health, Co-Developer. 1992-1993. $6,460.

Gordon J. Vanscoy
Page 62
Development of an antithrombotic traineeship program for medical residents. DuPont Pharma,
Educational Grant, Principal Developer and Program Administrator. 1992-1993. $15,000.
Development of a community-based drug information and compliance center. Thrift Drug Co.,
Educational Grant, Co-Developer. 1992-1993. $4,000.
Pharmaceutical Partnership Campaign. Multiple industry sources, Educational Grant, Principal
Developer. 1993. $7,500.
Establishing a computer network facility for pharmacy students. University of Pittsburgh School of
Pharmacy, Co-Developer. 1993. $5,000.
Development of a migraine quality of life and pharmacoeconomic protocol. Glaxo Inc., Co-Principal
Investigator. 1993. $3,500.
Enhancing Drug InfoNet: A pharmacy school computer network. University of Pittsburgh School of
Pharmacy, Co-Developer. 1993. $10,000.
Reducing costs through database sharing: Remote-site access to Tomes®. University of Pittsburgh
Department of Environmental and Occupational Health, Co-Developer. 1993-1994. $4,040.
Development and maintenance of a national cardiology educational network: Evolving therapeutic
strategies in acute myocardial infarction. Genentech Inc., Educational Grant, Developer and Program
Administrator. 1993-1994. $150,000.
Expert support to a community-based drug information and compliance center. Thrift Drug Co.,
Educational Grant, Co-Developer. 1993-1994. $2,000.
Pharmaceutical Partnership Campaign. Multiple industry sources, Educational Grant, Principal
Developer. 1993-1994. $16,500.
Comparative drug monographs. Express Pharmacy Services Medical Advisory Board, Developer. 1993-
1994. $16,500.
Replacing the use of slides with computer technology. University of Pittsburgh Pharmacy Associates,
Developer. 1994. $8,000.
National drug information strategic planning retreat. Marion Merrell Dow, Inc., Genentech, Inc. 1994.
$16,000.
Are neighborhood pharmacists solving drug-related problems? University of Pittsburgh Central Research
and Development Fund, Consultant. 1994-1995. $13,270.
Development of anticoagulant standards of practice pocket-card. DuPont Pharma, Educational Grant,
Principal Developer. 1994-1995. $2,750.
Expert support to a community-based drug information and compliance center. Thrift Drug Co.,
Educational Grant, Co-Developer. 1994-1995. $2,000.

Gordon J. Vanscoy
Page 63
Comparative drug monographs. Express Pharmacy Services Medical Advisory Board, Developer. 1994.
$4,500.
Enhancing a regional antithrombotic traineeship program for medical residents. DuPont Pharma,
Educational Grant, Principal Developer and Program Administrator. 1993-1995. $5,000.
Maintenance of a national cardiology educational network: Evolving therapeutic strategies in acute
myocardial infarction. Genentech Inc., Educational Grant, Program Administrator. 1994-1995.
$127,000.
Reducing costs through database sharing: Remote-site access to Tomes ® . University of Pittsburgh
Department of Environmental and Occupational Health, Co-Developer. 1994-1995. $4,040.
University of Pittsburgh ETSAMI program faculty retreat. Genentech, Inc., Educational Grant, Program
Administrator. 1995. $43,464.
Maintenance of a national cardiology educational network: Evolving therapeutic strategies in acute
myocardial infarction. Genentech Inc., Educational Grant, Program Administrator. 1995-1996.
$372,212.
An automated pharmacoeconomic analysis for remifentanil. Glaxo, Inc., Co-Investigator. 1995-1997.
$77,844.
Establishing a model practice in managed pharmaceutical care. Multiple industry sources. Stadtlanders
Development Funding. 1995-1996. $22,500.
Enhancing a regional antithrombotic traineeship program for medical residents. DuPont Pharma,
Educational Grant, Program Administrator. 1995-1996. $7,000.
CAMIPR national meeting. Hoechst Marion Roussel. Co-Program Administrator. 1996. $750.
National smoking cessation specialist certificate program. SmithKline Beecham Consumer Healthcare,
L.P., Educational Grant, Program Administrator. 1996-1997. $1,000,000.
Maintenance of a national cardio/cerebrovascular educational network: Focus on myocardial infarction
and stroke. Genentech, Inc. Educational Grant, Program Administrator. 1996-1997. $451,566.
Antithrombotic traineeship for medical residents. DuPont-Merck Pharmaceuticals. Educational Grant,
Program Administrator. 1996-1997. $5,000.
Maintenance of a national cardio/cerebrovascular educational network: Focus on myocardial infarction
and stroke. Genentech, Inc. Educational Grant, Program Administrator. 1997 Supplement. $157,756.
National smoking cessation specialist certificate program. SmithKline Beecham Consumer Healthcare,
L.P., Educational Grant, Program Administrator. 1997 Supplement. $148,800.
Twelfth annual national pharmacy invitational conference on anticoagulation therapy. DuPont Pharma.
Educational Grant, Program Administrator. 1997. $25,000.

Gordon J. Vanscoy
Page 64
Stadtlanders HIV/AIDS pharmacy certification program. Bristol-Myers Squibb, Program Administrator.
1997. Stadtlanders Development Funding. $75,000.
Maintenance of a national cardio/cerebrovascular educational network: Focus on myocardial infarction
and stroke. Genentech, Inc. Educational Grant, Program Administrator. 1998. $421,620.
National smoking cessation specialist certificate program. SmithKline Beecham Consumer Healthcare,
L.P., Educational Grant, Program Administrator. 1998. $914,606.
Stadtlanders transplant pharmacy certification program: Part II. Bristol-Myers Squibb, Program
Administrator. Stadtlanders Development Funding. 1998. $80,000.
Medication compliance in organ transplant recipients. Academic Research Enhancement Award,
Department of Health and Human Services, Public Health Service, Co-Principal Investigator. 1997-1999.
$107,171.
Maintenance of a national cardio/cerebrovascular educational network: Focus on myocardial infarction
and stroke. Genentech, Inc. Educational Grant, Program Administrator. 1999. $573,315.
National smoking cessation specialist certificate program. SmithKline Beecham Consumer Healthcare,
L.P., Educational Grant, Program Administrator. 1999. $899,753.
Peripheral arterial occlusion internet/homestudy educational program. Genentech, Inc. Educational
Grant, Program Administrator. 1999. $79,995.
European smoking cessation specialist program. SmithKline Beecham Consumer Healthcare, L.P.
Educational Grant, Program Administrator. 1999. $20,569.
Maintenance of a national cardio/cerebrovascular educational network: Focus on myocardial infarction,
stroke, and PAO/CVCC. Genentech, Inc. Educational Grant, Program Administrator. 2000. $757,450.
National smoking cessation specialist certificate program. SmithKline Beecham Consumer Healthcare,
L.P., Educational Grant, Program Administrator. 2000. $1,217,913.
Hospital pharmacy for the 21 st century: Transitioning your department/homestudy educational program.
Genentech, Inc. Educational Grant, Program Administrator. 2000. $40,000.
Formulary analysis of TNK-tPA. Genentech, Inc. Educational Grant. Program Administrator. 2000.
$12,500.
Maintenance of a national cardio-thromboembology educational network: Focus on infarction and
peripheral arterial/catheter thrombosis. Genentech, Inc. Educational Grant, Program Administrator.
2001. $655,875.
National smoking cessation specialist certificate program. SmithKline Beecham Consumer Healthcare.
L.P., Educational Grant, Program Administrator. 2001. $388,616.
Regional smoking cessation specialist initiative. Cuyahoga County OH Health Department. Educational
Grant, Program Administrator. 2001. $6,818.

Gordon J. Vanscoy
Page 65
Regional smoking cessation specialist initiative. Tompkins County NY Health Department. Educational
Grant, Program Administrator. 2001. $6,818.
Regional smoking cessation specialist initiative. United Health Services Hospitals. Educational Grant,
Program Administrator. 2001. $12,000.
Regional smoking cessation specialist initiative. Northern New York Rural Health Care Alliance.
Educational Grant, Program Administrator. 2001. $6,818.
Maintenance of a national cardio-thromboembology educational network: Focus on infarction and
peripheral arterial/catheter thrombosis. Genentech, Inc. Educational Grant, Program Administrator.
2002. $672,495.
AMCP spirit of volunteerism award grant. University of Pittsburgh AMCP Student Chapter. 2002. $500.
Regional smoking cessation specialist initiative. Smoke Free Mohawk Valley. Educational Grant,
Program Administrator. 2002. $6,818.
Regional smoking cessation specialist initiative. North Country Prenatal/Perinatal Council, Inc.
Educational Grant, Program Administrator. 2002. $6,816.
Smoking cessation specialist program continuing education presentation. Los Atlos Hills, California.
Educational Grant, Program Administrator. 2002. $5,680.
Regional smoking cessation specialist initiative. Foothill – De Anza Community College. Educational
Grant, Program Administrator. 2002. $6,816.
Maintenance at a national cardio-thromboembology educational network: Fibrinolysis update: Making
informed formulary decisions. Genentech, Inc. Educational Grant, Program Administrator. 2003.
$349,702.
Making informed formulary decisions with fibrolytics: Six GPO perspectives. Genentech, Inc.
Educational Grant, Program Administrator. 2003. $72,000.
AMCP student chapter P&T committee competition. Academy of Managed Care Pharmacy. Grant
Stipend, Program Administrator. 2003. $2,500.
Regional smoking cessation specialist initiative. County of Erie. Educational Grant, Program
Administrator. 2003. $6,816.
Maintenance at a national cardio-thromboembology educational network: Fibrinolysis update: Making
informed formulary decisions. Genentech, Inc. Educational Grant, Program Administrator. 2003.
(supplement) $30,720.
Regional smoking cessation specialist initiative. Watertown, NY. Educational Grant, Program
Administrator. 2004. $6,816.

Gordon J. Vanscoy
Page 66
Regional smoking cessation specialist initiative. Austin, TX. Educational Grant, Program Administrator.
2004. $6,816.
AMCP student chapter P&T committee competition. Academy of Managed Care Pharmacy. Grant
Stipend, Program Administrator. 2004. $2,500.
Maintenance at a national cardio-thromboembology educational network: Fibrinolysis update: Making
informed formulary decisions. Genentech, Inc. Educational Grant, Program Administrator. 2004.
$355,174.
AMCP student chapter P&T committee competition. Academy of Managed Care Pharmacy. Grant
Stipend, Program Administrator. 2005. $2,500.
Maintenance at a national cardio-thromboembology educational network: Concisely evaluating a
formulary class across indications: The new fibrinolytic model. Genentech, Inc. Educational Grant,
Program Administrator. 2005. $360,909.
Faxton-St. Lukes Healthcare: Regional smoking cessation specialist initiative. Utica, NY. Educational
Grant, Program Administrator. 2005. $6,816.
Arnot Ogden Medical Center: Regional smoking cessation specialist initiative. Elmira, NY. Educational
Grant, Program Administrator. 2005. $6,816.
HCA Genesis: Regional smoking cessation specialist initiative. Watertown, NY. Educational Grant,
Program Administrator. 2005. $6,816.
Southern Tier Health Care System: Regional smoking cessation specialist initiative. Olean, NY.
Educational Grant, Program Administrator. 2005. $6,816.
American Lung Association of New York State: Regional smoking cessation specialist initiative.
Albany, NY. Educational Grant, Program Administrator. 2005. $12,000.
Faxton-St. Luke’s Healthcare: Regional smoking cessation specialist initiative. Utica, NY. Educational
Grant, Program Administrator. 2006. $13,632.
Southern Tier Health Care System, Inc. : Regional smoking cessation specialist initiative. Olean, NY.
Educational Grant, Program Administrator. 2006. $6,816.
Arnot Ogned Medical Center: Regional smoking cessation specialist initiative. Elmira, NY. Educational
Grant, Program Administrator. 2006. $6.816.
AMCP student chapter P&T committee competition. Academy of Managed Care Pharmacy. Grant
Stipend, Program Administrator. 2006. $2,500.
St. Joseph’s Hospital Health Center: Regional smoking cessation specialist initiative. Syracuse, NY.
Educational Grant, Program Administrator. 2006. $6,816.
United Health Services Hospitals: Regional smoking cessation specialist initiative. Binghamton, NY.
Educational Grant, Program Administrator. 2006. $6,816.

Gordon J. Vanscoy
Page 67
Maintenance at a national cardio-thromboembology educational network: Concisely evaluating a
formulary class across indications: The new fibrinolytic model. Genentech, Inc. Educational Grant,
Program Administrator. 2006. $3,017.
GRANT PROPOSALS NOT FUNDED OR PENDING
Smoking cessation training program. March of Dimes Community Grants, Investigator. 2001. $11,958.
(not funded)
Prenatal smoking cessation clinician training manual. American College of Obstetricians and
Gynecologists, Program Administrator. 2001. $478,452. (not funded)
Medication compliance assessment in transplant recipients. Central Research Development Fund,
University of Pittsburgh, Co-Principal Investigator. 1995-1996. $10,680. (not funded)
Expansion of Drug InfoNet access via Pittnet Ports. University of Pittsburgh Computing and Information
Services, Co-Developer. 1994. $6,400. (not funded)
Enhancement of a model drug information and pharmacoepidemiology center. The Merck Foundation,
Educational Grant, Principal Developer. 1993. (not funded)
Enhancement of QMR to diagnose phenytoin toxicity. University of Pittsburgh Section of Medical
Informatics, Co-Principal Investigator. 1994. (not funded)
Expansion of Drug InfoNet access via Pittnet Ports. University of Pittsburgh Computing and Information
Services, Co-Developer. 1993. $6,400. (not funded)
Expansion of Drug InfoNet access via Pittnet Ports. University of Pittsburgh Computing and Information
Services, Co-Developer. 1992. $7,500. (not funded)
Enhancing the computerized clinical drug information network. University of Pittsburgh Faculty
Computing Proficiency Enhancement Program. Principal Developer. 1992. $11,648. (not funded)